US Pat. No. 10,556,014

COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT

ELLIPSES PHARMA LIMITED, ...

1. A compound or pharmaceutically acceptable salt thereof, comprising a compound X which promotes the formation of stable microtubules in a manner similar to paclitaxel associated with a peptide Y comprising a matrix metalloproteinase cleavage site comprising the amino acid sequence -Arg-Ser-Cit-Gly-Hof-Tyr-Leu- (SEQ ID NO: 4).
US Pat. No. 10,557,040

ANTI-CORROSION COATINGS LOADED WITH MESOSTRUCTURED PARTICLES

AIRBUS, Blagnac (FR)

1. A coating comprising at least one layer comprising individual and mesostructured spherical micrometric particles, said mesostructured spherical micrometric particles being loaded with at least one element selected from among functional corrosion-inhibiting molecules and functional corrosion-inhibiting nano-objects and formed by a continuous non-dissociable nebulization of a liquid solution at a predetermined molar concentration in a solvent to obtain a fog of solution droplets and heating the fog solution droplets to evaporate the solvent and volatile compounds in a single reactor, the liquid solution comprising one or more precursors from a three-dimensional network of particles and said at least one element chosen from the functional corrosion-inhibiting molecules and the functional corrosion-inhibiting nano-objects; and wherein said at least one layer is a sealed hybrid organic-inorganic layer, containing a sol-gel or sealed primer layer, that is closed and sealed to limit penetration of corrosive materials.
US Pat. No. 10,556,015

LYSOSOMAL TARGETING OF ENZYMES, AND USES THEREOF

Criteo S.A., Paris (FR)

1. A targeted therapeutic fusion protein comprising a lysosomal enzyme fused to a lysosomal targeting moiety comprising a proprotein convertase subtilisin kexin type 9 (PCSK9) protein comprising amino acid substitutions S386A and F379A.
US Pat. No. 10,557,041

ANTI-CORROSION COMPOSITION COMPRISING POLYISOBUTYLENES

1. Anti-corrosion composition comprising:at least a first polyisobutylene with a Staudinger index J0 ranging from about 15 cm3/g to about 98 cm3/g and an average relative molar mass Mv ranging from about 32,000 g/mol to about 280,000 g/mol and at least a second polyisobutylene with a Staudinger index J0 ranging from about 105 cm3/g to about 238 cm3/g and an average relative molar mass Mv ranging from about 350,000 g/mol to about 900,000 g/mol and at least a third polyisobutylene with a Staudinger index J0 ranging from about 240 cm3/g to about 900 cm3/g and an average relative molar mass Mv ranging from about 950,000 g/mol to about 5,500,000 g/mol.
US Pat. No. 10,556,016

ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR PRODUCING AND USING THE SAME

Indiana University Resear...

1. A biomimetic Janus particle comprising:a) a particle;
b) at least one substantially concentric pattern of a first ligand population bound to the particle, wherein the first ligand population comprises one or more ligands involved in T cell activation and/or one or more molecules to which a ligand involved in T cell activation may be bound; and
c) a second ligand population bound to the particle, wherein the second ligand population is different than the first ligand population and does not substantially overlap the substantially concentric pattern of the first ligand population, and wherein the second ligand population comprises one or more ligands involved in T cell activation and/or one or more molecules to which a ligand involved in T cell activation may be bound,
wherein one of the first ligand population or second ligand population comprise an integrin-binding ligand.
US Pat. No. 10,557,042

SLIPPERY LIQUID-INFUSED POROUS SURFACES THAT PREVENT MICROBIAL SURFACE FOULING

Wisconsin Alumni Research...

1. A slippery liquid-infused porous surface (SLIPS) that controllably releases a molecule, wherein said slippery oil-infused surface comprises:a) a porous matrix having nanoscale or microscale porosity;
b) an oil covering at least a portion of the porous matrix, wherein said oil at least partially fills the pores of the porous matrix; and
c) one or more small-molecule compounds, wherein the one or more small-molecule compounds are located on the surface or in said porous matrix, within said oil, or both,
wherein the slippery oil-infused surface is able to controllably release the one or more small-molecule compounds when the slippery oil-infused surface is immersed into media.
US Pat. No. 10,557,043

TEMPERATURE-SENSITIVE NANO SILVER CONTROLLED-RELEASE SMART ANTIBACTERIAL COATING AND PREPARATION METHOD THEREFOR

FU ZHOU UNIVERSIT, Fuzho...

1. A temperature-sensitive nano-silver controlled release antibacterial coating composite comprising:25˜35 parts by weight of water,
30˜40 parts by weight of acrylic,
20˜30 parts by weight of polyurethane resin,
2˜3 parts by weight of temperature-sensitive nano-silver controlled release antibacterial agent,
1.5˜2.5 parts by weight of dispersant,
1.0˜1.5 parts by weight of curing agent,
0.8˜1.0 parts by weight of defoamer,
0.5˜0.8 parts by weight of filming additive, and
0.5˜0.8 parts by weight of leveling agent;
wherein the temperature-sensitive nano-silver controlled release antibacterial agent is nano-silver adsorbed to particles of nanometer mesoporous SiO2 modified by poly N-isopropyl acrylamide;
above 32° C. poly N-isopropyl acrylamide on the surface of nano-mesoporous SiO2 particles will shrink, blocking the mesopores and thus preventing the release of internal nano-Ag: when the temperature is below 32° C. poly N-isopropyl acrylamide on the surface of nano-mesoporous SiO2 particles will be in the dilated state, the release of internal nano-Ag becomes unimpeded, so that controlled release of nano Ag can be achieved.
US Pat. No. 10,555,506

NON-HUMAN MAMMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES

ABLEXIS, LLC, San Diego,...

1. A mouse whose genome comprises a transgene comprising an immunoglobulin heavy chain (IgH) locus, or a portion thereof, wherein said IgH locus comprises in operable linkage from 5? to 3? an unrearranged DNA sequence of a human variable heavy (VH) gene segment, a diversity heavy (DH) gene segment, and a human joining heavy (JH) gene segment, operably linked to a constant region gene comprising a human CH1 exon, a human Cupper hinge exon, a human or mouse Cmiddle hinge exon, a mouse CH2 exon and a mouse CH3 exon, wherein the human CH1 exon is selected from the group consisting of a human mu constant region (C?) CH1 exon, a human delta constant region (C?) CH1 exon, a human gamma-1 constant region (C?l) CH1 exon, a human gamma-2 constant region (C?2) CH1 exon, a human gamma-4 constant region (C?4) CH1 exon, a human alpha constant region (C?) CH1 exon, and a human epsilon constant region (C?) CH1 exon, wherein the IgH locus further comprise an IgH non-coding region and wherein during B cell development, the IgH locus undergoes gene rearrangement and expresses a chimeric immunoglobulin heavy chain comprising a human heavy chain variable domain and a chimeric IgH constant domain.
US Pat. No. 10,555,507

NON-HUMAN ANIMALS HAVING HUMANIZED FC-GAMMA RECEPTORS

Regeneron Pharmaceuticals...

1. A mouse whose genome comprises an Fc?RI gene at an endogenous Fc?RI locus, wherein the Fc?RI gene encodes a functional Fc?RI protein comprising an extracellular portion of a human Fc?RI ? chain and an intracellular portion of a mouse Fc?RI ? chain, wherein the mouse expresses the functional Fc?RI protein encoded by the Fc?RI gene.
US Pat. No. 10,556,019

HUMAN MICRORNAS FOR TREATMENT OF MALIGNANT TUMOURS

1. A method of treatment of breast cancer, comprising:administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule consisting essentially of a sequence selected from the group consisting of SEQ ID NO 001 and SEQ ID NO 002,wherein the nucleic acid molecule initiates apoptosis in cancerous cells, thereby treating the breast cancer.
US Pat. No. 10,557,045

PIGMENT DISPERSANT WITH HINDERED LIGHT AMINE STABILIZER AND PIGMENT DISPERSIONS AND COATING COMPOSITIONS BASED THEREON

PPG Industries Ohio, Inc....

1. A pigment dispersion comprising (a) at least one pigment and (b) a polymeric dispersant comprising residual units derived from polymerization of a mixture of monomers comprising (b1) at least one ethylenically unsaturated hindered amine light stabilizing monomer and (b2) at least one additional ethylenically unsaturated monomer different from monomer (b1),wherein the polymeric dispersant further comprises at least one linkage in the polymer selected from an ester linkage, an ether linkage or a combination thereof.
US Pat. No. 10,555,508

IN VIVO METHOD FOR GENERATING DIVERSITY IN A PROTEIN SCAFFOLD

CRYSTAL BIOSCIENCE INC., ...

1. A transgenic chicken comprising a genome comprising an immunoglobulin heavy chain locus comprising:(a) a transcribed gene encoding a fusion protein comprising, from N-terminus to C-terminus: a binding domain from a heavy chain-only antibody and, operably linked to said binding domain, at least part of a heavy chain constant region that is native to said transgenic chicken; and
(b) a plurality of pseudogenes that are operably linked to said transcribed gene and that donate, by gene conversion, nucleotide sequence to the part of said transcribed gene that encodes said binding domain, wherein the pseudogenes are upstream or downstream of the transcribed gene and contain a nucleotide sequence that is at least 80% identical to at least part of the transcribed gene;
wherein the genome of the chicken further comprises an immunoglobulin light chain locus that encodes a light chain constant region but not a light chain variable domain, and
wherein the transgenic chicken produces a diversified population of antibodies whose binding specificity is solely determined by a diversified binding domain of (a).
US Pat. No. 10,556,020

RNA-MODULATING AGENTS

UNIVERSITY OF MASSACHUSET...

1. An RNA-modulating agent comprising an mRNA binding sequence that is complementary to a portion of a target mRNA sequence, linked to two or more miRNA binding sequences, wherein one or more of the miRNA binding sequences are complementary to positions 2 to 8, and 12 to 15, 12 to 16, or 12 to 17 of the miRNA, but not complementary to positions 1, 10 and 11 of the miRNA.
US Pat. No. 10,556,022

IMAGEABLE POLYMERS

Biocompatibles UK Ltd., ...

1. Hydrogel polymer microspheres wherein the hydrogel polymer comprises: a polyvinyl alcohol (PVA) backbone comprising at least two pendant chains having cross-linkable ethylenically unsaturated functional groups which are cross linked by a vinylic co-monomer;wherein the PVA comprising 1,3 diol groups is acetalised with a radiopaque species which is coupled to the hydrogel polymer through a cyclic acetal group, the radiopaque species comprising one or more covalently bound iodines.
US Pat. No. 10,557,048

INKS

Fujifilm Imaging Colorant...

1. An ink comprising:(a) from 0.5 to 5 parts of a self-dispersible pigment;
(b) from 5 to 8 parts of a styrene acrylic latex binder;
(c) from 0 to 5 parts of a glycol selected from the group consisting of ethylene glycol, diethylene glycol, propylene glycol, dipropylene glycol or triethylene glycol;
(d) from 1 to 10 parts of 2-pyrrolidone;
(e) from 1 to 15 parts of glycerol;
(f) from 0.1 to 0.5 parts of 2,4,7,9-tetramethyl-5-decyne-4,7-diol or an ethylene oxide condensate thereof;
(g) from 0.001 to 5 parts of biocide;
(h) from 0 to 10 parts of a polyethylene glycol; and
(i) the balance to 100 parts water, wherein the ink has a surface tension of from 30 to 40 dynes/cm when measured at 25° C. using a Kruss K100 tensiometer.
US Pat. No. 10,556,024

18F LABELING OF PROTEINS USING SORTASES

Whitehead Institute for B...

1. A method for labeling a protein having a sortase recognition motif comprising:contacting the protein with a sortase substrate peptide in the presence of a sortase to transamidate the protein and the sortase substrate peptide, wherein the sortase substrate peptide comprises a click chemistry handle; and
contacting the protein with a radiolabeled agent, wherein the radiolabeled agent comprises a click chemistry handle which reacts with the click chemistry handle of the protein, thereby producing a radiolabeled protein,
wherein the radiolabeled agent comprises fluorodeoxyglucose (18F-FDG), and wherein the click chemistry handle is linked to the fluorodeoxyglucose via an oxime linkage;
wherein the protein comprises a C-terminal sortase recognition motif LPXTG or NPXTX, wherein each instance of X independently represents any amino acid residue, and the sortase substrate peptide comprises a N-terminal sortase recognition motif oligoglycine or oligoalanine;
wherein the sortase substrate peptide is linked to the radiolabeled agent by an oxime linkage, a hydrazone linkage, a thiosemicarbazone linkage, a heterocyclylene linkage, an amide linkage, an ester linkage, an ether linkage, or a disulfide linkage.
US Pat. No. 10,557,818

CEPHALOPOD PROTEINS AS PROTON CONDUCTORS

The Regents of the Univer...

1. A protonic transistor, comprisinga source electrode;
a drain electrode;
a protonic channel structure comprising a cephalopod proton-conducting protein comprising SEQ ID NO: 1 and/or a reflectin; and
a gate electrode in contact with or in proximity to the protonic channel structure.
US Pat. No. 10,557,051

METHOD FOR PRODUCING AN INK, INK, AND USE OF SAME

FORSCHUNGSZENTRUM JUELICH...

1. A method for producing an ink, comprising:a) producing, via a wet milling process using a first solvent, nanoparticles having a size of 0.1 to 20 nm;
b) covalently bonding, by coupling reactions, short-chain, branched organic stabilizer molecules to surfaces of the nanoparticles to form stabilized nanoparticles; and
c) forming the ink by dissolving the stabilized nanoparticles in a second solvent and dispersing the stabilized nanoparticles in the second solvent.
US Pat. No. 10,557,053

UNIVERSAL PIGMENT PREPARATIONS FOR POINT-OF-SALE USE

BASF SE, Ludwigshafen (D...

1. A pigment preparation comprising, based in each case on the total weight of the preparation,(A) 1 to 80 wt % of a pigment component which comprises a pigment and optionally a filler;
(B) 0.01 to 10 wt % of a water-soluble, anionic, surface-active additive selected from the group consisting of homo- and copolymers of ethylenically unsaturated monocarboxylic acids and/or ethylenically unsaturated dicarboxylic acids, which may further comprise, in copolymerized form, vinyl monomers comprising no acid function, and of the salts of the homo- and copolymers, the homo- and copolymers being at least partly esterified with a polyether alcohol or a derivative thereof;
(C) 0.01 to 8 wt % of a phosphoric ester of the formula (I):
[RO—(C2-C3-alkylene oxide)y]x-PO(OH)3-x  (I)
wherein
the radical R independently at each occurrence is linear or branched C8-C22-alkyl, C8-C22-alkenyl or phenyl which may be substituted by C1-C12-alkyl, styryl or methyl-substituted styryl,
the (C2-C3-alkylene oxide) group is ethylene oxide and/or propylene oxide,
x=1 or 2, and
y=1-100;
(D) 0 to 20 wt % of one or more further additives customary for aqueous pigment preparations; and
(E) water,
where the sum of the percentages by weight of components (A) to (E) makes 100 wt %.
US Pat. No. 10,556,798

SYNTHESIS OF FLUORINATED GRAPHENE OXIDE FOR ELECTROCHEMICAL APPLICATIONS

LAKEHEAD UNIVERSITY, Thu...

1. A method for synthesis of about 0.5 to about 1.5 at. % fluorinated grapheme oxide comprising:mixing about n grams of graphite with about 5*n to about 40*n ml HF in a solution of about 50*n to about 150*n ml of H2SO4/H3PO4 at a ratio of 10-x:x, where x=0.1 to 4 with stirring at a temperature of about 30 to about 80° C. for a first period of time to generate a first mixture;
adding about 3*n to about 10*n g KMnO4 to the first mixture to generate a second mixture and stirring the second mixture at a temperature of about 40 to about 80° C. for a second period of time;
adding the second mixture to a container containing about 50*n to about 250*n ml of ice and about 1*n to about 10*n ml of H2O2 to generate a third mixture;
separating solid comprising about 0.5 to about 1.5 at. % fluorinated grapheme oxide from the third mixture;
rinsing the fluorinated graphene oxide; and
drying the fluorinated graphene oxide.
US Pat. No. 10,556,799

TRITERTBUTYL ALUMINUM REACTANTS FOR VAPOR DEPOSITION

ASM IP HOLDING B.V., Alm...

1. A deposition reactor comprising a first reactant container fluidly connected to a reaction chamber, the reactant container comprising a first precursor composition comprising at least 50% Isomer 1, at least 50% Isomer 2, or at least 20% of a combination of Isomer 1 and Isomer 2 of Al(tert-Bu)3, wherein Isomer 1 has the formula Al(tert-Bu)2(iso-Bu) and Isomer 2 has the formula Al(tert-Bu)(iso-Bu)2.
US Pat. No. 10,557,055

CONFORMABLE COATING COMPOSITION COMPRISING FLUORINATED COPOLYMER

3M Innovative Properties ...

1. A conformable coating composition comprising:a (meth)acrylate copolymer comprising interpolymerized monomer units of 2,2,2-trifluoroethyl acrylate in an amount ranging from 10-40 wt-% based on the weight of the (meth)acrylate copolymer; and
a volatile solvent having a solubility parameter from 4.9-12.5 (cal/cm3)1/2, wherein the volatile solvent is selected from the group consisting of volatile linear and cyclic siloxanes, volatile polydimethylsiloxanes, isooctane, octane, and combinations thereof, and
wherein the conformable coating composition is free of polymerizable cyanoacrylate monomer.
US Pat. No. 10,555,519

NON-TOXIC LARVICIDE

STC.UNM, Albuquerque, NM...

1. A larvicidal capsule comprising an essential oil encapsulated in a non-viable yeast cell and wherein the larvicidal capsule is coated with a soluble silica coating.
US Pat. No. 10,557,057

HIGH MELT FLOW PAEK COMPOSITIONS

SOLVAY SPECIALTY POLYMERS...

1. A composition (C) comprising:a. from 20 to 80% by weight (wt. %) of at least one poly(aryl ether ketone) polymer, (PAEKHMF) polymer, having a melt flow rate (MFR) from 15 g/10 min to 80 g/10 min at 400° C. and under a load of 2.16 kg, as measured in accordance with ASTM method D1238;
b. from 12 to 30 wt. % of at least one poly(tetrafluoroethylene) polymer, (PTFE) polymer, having a D50 particle size from 2 to 8 ?m, and having a melting temperature (TmII) from 321° C. to about 324° C.; and
c. from 10 to 30 wt. % of at least one carbon fiber,
and wherein all wt. % are based on a total weight of the composition (C).
US Pat. No. 10,555,520

PESTICIDE COMPOSITION POTENTIATED IN EFFICACY AND METHOD FOR POTENTIATING EFFICACY OF PESTICIDAL ACTIVE INGREDIENTS

Nippon Soda Co., Ltd., T...

1. A method for potentiating the efficacy of acetamiprid, comprisingpreparing a composition consisting of a compound represented by formula (I), an acetamiprid, and a solvent: and dispersing the composition,
formula (I) having the following structure:
R—O-(EO)w-(PO)x-(EO)y-(PO)z-H  (I)
wherein, EO represents an ethyleneoxy group, PO represents a propyleneoxy group, R represents a dodecyl group or tridecyl group, w represents on average an integer in the range of 1 to 25, x represents on average an integer in the range of 1 to 25, y represents on average an integer in the range of 1 to 25, and z represents on average an integer in the range of 1 to 25*
wherein a ratio of the compound represented by formula (I) to the acetamiprid is 15/1 to 10/1, andwherein a hydrophilic-lipophilic balance of the compound represented by formula (I) is 12.3.
US Pat. No. 10,557,059

SLURRY, POLISHING-SOLUTION SET, POLISHING SOLUTION, SUBSTRATE POLISHING METHOD, AND SUBSTRATE

HITACHI CHEMICAL COMPANY,...

1. A slurry comprising:an abrasive grain; and
water, wherein
the abrasive grain includes a hydroxide of a tetravalent metal element, produces absorbance of 1.00 or more and less than 1.50 for light having a wavelength of 400 nm in an aqueous dispersion having a content of the abrasive grain adjusted to 1.0 mass %, and produces absorbance of 0.035 or more for light having a wavelength of 400 nm in a liquid phase obtained when centrifuging an aqueous dispersion having a content of the abrasive grain adjusted to 1.0 mass % for 50 minutes at a centrifugal acceleration of 1.59×105 G.
US Pat. No. 10,555,522

LONG TERM METHODS OF IMPROVING DISEASE TOLERANCE IN PLANTS

AgroFresh Inc., Collegev...

1. A method of improving long-term disease tolerance of a crop plant, said method comprising:contacting the crop plant with a composition comprising 1-methylcyclopropene (1-MCP),
wherein the crop plant is a pre-transplant seedling having about 3 leaves or about 4 leaves,
wherein the pre-transplant seedling is a young plant sporophyte that has developed out of a plant embryo from a seed,
transplanting the pre-transplant seedling, and
improving the long-term disease tolerance of the crop plant treated with the composition comprising 1-MCP as compared to a crop plant that is not treated with the composition comprising 1-MCP,
wherein the improvement in the long-term disease tolerance of the treated crop plant is selected from the group consisting of an improvement in a fungal disease tolerance, a bacterial disease tolerance, a viral disease tolerance, or a combination thereof, and
wherein the long-term disease tolerance is present in the treated crop plant between 6-12 weeks after contacting the pre-transplant seedling with the composition comprising 1-MCP.
US Pat. No. 10,557,060

METHOD OF CHEMICAL MECHANICAL POLISHING A SUBSTRATE

Rohm and Haas Electronic ...

1. A method of polishing a substrate, comprising:providing the substrate, wherein the substrate comprises tungsten (W) and titanium (Ti);
providing a chemical mechanical polishing composition, consisting of, as initial components:
water;
an oxidizing agent;
an allylamine additive selected from the group consisting of poly(allylamine hydrochloride) and poly(allylamine);
a colloidal silica abrasive having a permanent positive surface charge;
a carboxylic acid;
a source of iron (III) ions; and,
optionally, a pH adjusting agent; and wherein the chemical mechanical polishing composition has a pH of 1 to 4;
providing a chemical mechanical polishing pad, having a polishing surface;
creating dynamic contact at an interface between the chemical mechanical polishing pad and the substrate; and
dispensing the chemical mechanical polishing composition onto the polishing surface of the chemical mechanical polishing pad at or near the interface between the chemical mechanical polishing pad and the substrate;
wherein at least some of the tungsten (W) is polished away from the substrate at a tungsten (W) removal rate; wherein at least some of the titanium (Ti) is polished away from the substrate at a titanium (Ti) removal rate; wherein the chemical mechanical polishing composition provided has a removal rate selectivity for the tungsten (W) versus the titanium (Ti); and, wherein the tungsten (W) removal rate is ?35 times higher than the titanium (Ti) removal rate.
US Pat. No. 10,555,523

SELF INDICATING ANTIMICROBIAL CHEMISTRY

Ecolab USA Inc., Saint P...

7. A method of indicating the presence of a peroxycarboxylic acid concentration for surface disinfection comprising:generating a peroxycarboxylic acid in situ by perhydrolysis;
contacting a latent dye of a visual indicator composition with a peroxycarboxylic acid to oxidize the latent dye; and
indicating a presence of a desired concentration of the peroxycarboxylic acid for surface disinfection through the visual indicator composition comprising at least two dyes, wherein the combination of dyes have different half-lives to provide sustained visual indication of peroxycarboxylic acid concentration for at least 12 hours.
US Pat. No. 10,556,294

METHOD OF TREATING SUPERALLOY ARTICLES

GENERAL ELECTRIC COMPANY,...

1. A method of treating a superalloy article, comprising:selecting an article having a superalloy composition, whereby said article has at least one treatable feature on its outermost surface;
removing a base alloy from a region abutting a portion of the at least one treatable feature to form a first treatment region and a second treatment region, wherein the base alloy has not been removed from the region abutting the second treatment region;
treating at least a portion of the second treatment region with a treatment composition including a silicon aluminum alloy or an aluminum fluoride derivative to form a clean second treatment region;
inserting a treatment material into the first treatment region;
depositing the base alloy into the first treatment region;
heating the article to a temperature above the melting point of the treatment material thereby allowing the molten treatment material to flow into the clean second treatment region to form a treated article.
US Pat. No. 10,555,525

METHOD OF IMPROVING TURFGRASS ABIOTIC STRESS TOLERANCE

Syngenta Participations A...

1. A method for controlling or suppressing abiotic stress in turfgrass, comprising applying to the turfgrass or to the locus of the turfgrass, a turf quality improving non-phytotoxic amount of a composition comprising a mixture of acibenzolar-S-methyl and fluazinam, wherein the acibenzolar-S-methyl is applied at a rate of from 4 to 20 g/ha.
US Pat. No. 10,557,063

DOUBLE-SIDED BLACK ADHESIVE TAPE

Dexerials Corporation, T...

1. A double-sided black adhesive tape having a hollow particle-containing adhesive agent layer, wherein a surface of the hollow particle is coated with a layer of black pigment by being subjected to a black pigment adhesion treatment, the hollow particle-containing adhesive agent layer contains a black pigment-including resin particle including a black pigment having a particle volume average particle diameter of 1 to 20 ?m, and a content of the black pigment having a particle volume average particle diameter of 1 to 20 ?m is from 0.25 to 1.0% by mass to the black pigment-including resin particle,wherein the hollow particle-containing adhesive agent layer is a layer obtained by forming a layer from a hollow particle-containing adhesive agent composition containing a photocurable type acrylic adhesive agent composition containing (a) a monofunctional (meth)acrylate, (b) (meth)acrylic acid, (c) an acrylic crosslinking agent and (d) a photo-radical polymerization initiator, and a hollow particle a surface of which is subjected to a black pigment adhesion treatment, and photopolymerizing the layer;
wherein on one side or both sides of the hollow particle-containing adhesive agent layer is provided a hollow particle-free adhesive agent layer obtained by forming a layer from a photocurable type hollow particle-free adhesive agent composition containing a photocurable type acrylic adhesive agent composition containing (aa) a monofunctional (meth)acrylate, (bb) (meth)acrylic acid, (cc) an acrylic crosslinking agent and (dd) a photo-radical polymerization initiator, and photopolymerizing the layer;
wherein (c) the acrylic crosslinking agent and (cc) the acrylic crosslinking agent are respectively at least one selected from the group consisting of neopentyl glycol di(meth)acrylate, hydroxypivalic acid neopentyl glycol di(meth)acrylate, polypropylene glycol di(meth)acrylate, nonanediol di(meth)acrylate, 1,4-butanediol di(meth)acrylate, polyethylene glycol di(meth)acrylate and EO-modified polypropylene glycol di(meth)acrylate;
wherein (c) the acrylic crosslinking agent is different from (cc) the acrylic crosslinking agent;
wherein the monofunctional (meth)acrylate (a) is at least one selected from the group consisting of 2-ethylhexyl acrylate, butyl acrylate, isooctyl acrylate, isostearyl acrylate and ethyl carbitol acrylate;
wherein the monofunctional (meth)acrylate (aa) is at least one selected from the group consisting of 2-ethylhexyl acrylate, butyl acrylate, isooctyl acrylate, isostearyl acrylate and ethyl carbitol acrylate;
wherein the hollow particle-containing adhesive agent composition further contains ethyl carbitol acrylate as a flexibility imparting agent; and
wherein the photocurable type hollow particle-free adhesive agent composition further contains isostearyl acrylate as a flexibility imparting agent.
US Pat. No. 10,556,038

DERMATOLOGICAL ADHESIVE AGENT, PATCH MATERIAL, AND METHOD FOR PRODUCING DERMATOLOGICAL ADHESIVE AGENT

ALCARE CO., LTD, Tokyo (...

1. A dermal adhesive in the form of a porous membrane formed through irradiation of a radiation-curable resin with radiation rays, comprising:fibrous resins containing the radiation-curable resin;
particulate resins containing the radiation-curable resin;
a hydrophilic polymer dispersed in the radiation-curable resin;
a reactive diluent that reacts with the radiation-curable resin; and
a functional group-free acrylic polymer,
wherein the dermal adhesive has a porosity of 5 to 90% and voids between the fibrous resins and particulate resins,
wherein the radiation-curable resin is an ultraviolet ray-curable resin,
wherein in the dermal adhesive an amount of the radiation-curable resin is 35 to 95 mass %, an amount of the hydrophilic polymer is 1 to 30 mass %, an amount of the reactive diluent is 1 to 20 mass %, and an amount of the functional group-free acrylic polymer is 1 to 20 mass %, and
wherein the fiber diameter of each of the fibrous resins is from 1 to 1000 ?m, and the length of each of the fibrous resins is from 0.1 to 10 mm, and
wherein the particle size of each of the particulate resins is from 1 to 1000 ?m.
US Pat. No. 10,557,064

ELECTRON BEAM CURABLE PRESSURE SENSITIVE ADHESIVE COMPRISING ACRYLIC POLYMER WITH BOUND VINYL GROUP

Ashland Licensing and Int...

1. A process for making an electron beam (“e-Beam”) curable pressure sensitive adhesive (“PSA”) comprising the steps of derivatizing an acrylic polymer having one or more hydroxy groups or one or more acid groups with a derivatizing agent prepared from a hydroxy-functional acrylate monomer and a diisocyanate and curing the PSA with exposure to an e-Beam,wherein the acrylic polymer before derivatization has a glass transition temperature (Tg) ranged from about ?35° C. to about ?50° C.
wherein the PSA comprises no photoinitiator.
US Pat. No. 10,555,527

USE OF GLYPHOSATE FOR DISEASE SUPPRESSION AND YIELD ENHANCEMENT IN SOYBEAN

Monsanto Technology LLC, ...

1. A method for treating Soybean Sudden Death Syndrome comprising:a) identifying a soybean plant in a field infected with Fusarium virguliforme or Fusarium tucumaniae, the causal agents of Soybean Sudden Death Syndrome; and
b) treating the soybean plant with a formulation or mixture comprising glyphosate, whereby symptoms of Soybean Sudden Death Syndrome are suppressed by glyphosate;
wherein the field contains propagules of Fusarium virguliformae or Fusarium tucumaniae prior to or subsequent to planting, or subsequent to planting but prior to growth stage R1; and
wherein glyphosate is applied to the soybean plant after infection by Fusarium virguliformae or Fusarium tucumaniae.
US Pat. No. 10,555,528

HERBICIDAL COMPOSITION AND METHOD FOR CONTROLLING WEEDS

SUMITOMO CHEMICAL COMPANY...

1. A herbicidal composition comprising a PPO inhibitor and glufosinate or its salt, wherein the weight ratio of the PPO inhibitor to glufosinate or its salt is from 1/20,000,000 to 1/2,000,wherein the PPO inhibitor is saflufenacil or trifludimoxazin.
US Pat. No. 10,556,040

SURFACE-MODIFIED METAL AND METHOD FOR MODIFYING METAL SURFACE

SUMITOMO RUBBER INDUSTRIE...

1. A surface-modified metal which has a surface that is at least partially provided with a treatment layer having a thickness of 60 to 760 nm, the treatment layer being formed by treating a surface of a metal with a silane coupling agent, followed by adsorbing a hydrogen abstraction type photopolymerization initiator onto the surface and then polymerizing a monomer.
US Pat. No. 10,556,298

WELDED JOINT AND METHOD OF MANUFACTURING WELDED JOINT

NIPPON STEEL CORPORATION,...

1. A method of manufacturing a welded joint, comprising the steps of:preparing a base material having a chemical composition of, in mass %:
C: 0.005 to 0.1%;
Si: up to 1.2%;
Mn: 2.5 to 6.5%;
Ni: 8 to 15%;
Cr: 19 to 25%;
Mo: 0.01 to 4.5%;
V: 0.01 to 0.5%;
Nb: 0.01 to 0.5%;
Al: less than 0.05%;
N: 0.15 to 0.45%;
O: up to 0.02%;
P: up to 0.05%; and
S: up to 0.04%, and
a balance being iron and impurities,
preparing a welding material having a chemical composition consisting of, in mass %:
C: 0.005 to 0.1%;
Si: up to 0.7%;
Mn: 0.5 to 3%;
Ni: 8 to 23%;
Cr: 17 to 25%;
Mo: 0.01 to 4%;
V: 0 to 0.5%;
Nb: 0 to 0.5%;
Al: less than 0.05%;
N: less than 0.15%;
O: up to 0.02%;
P: up to 0.03%; and
s: up to 0.02%, and
a balance being iron and impurities, and
welding the base material using the welding material,
wherein the chemical composition of the base material satisfies Equation (1), and the chemical composition of the welding material satisfies Equations (1) and (2),
Ni+0.65Cr+0.98Mo+1.05Mn+0.35Si+12.6C?29  (1), and
0.31C+0.048Si?0.02Mn?0.056Cr+0.007Ni?0.013Mo??1.0  (2),
where the contents of elements (in mass %) are substituted for the symbols of these elements in Equations (1) and (2).
US Pat. No. 10,555,529

COMPOSITION FOR THE CONTROL OF GRAPEVINE ESCA DISEASE, BLACK DEAD ARM DISEASE, AND/OR EUTYPA DIEBACK DISEASE

RIKEN, Wako-Shi, Saitama...

1. A method for controlling at least one disease selected from grapevine ESCA disease, black dead arm disease, and Eutypa dieback disease, the method comprising applying to a grape a composition comprising potassium carbonate as an active ingredient.
US Pat. No. 10,556,299

FLUX AND RESIN COMPOSITION FOR FLUX

Senju Metal Industry Co.,...

1. A flux comprising:at least one selected from 0.3 to 2.0 mass % of an organochlorine compound, and more than 0.04 mass % and 1.00 mass % or less of an amine hydrochloride; and
0.2 to 1.5 mass % of an organophosphorus compound that is at least one selected from a phosphonic acid ester and a phenyl-substituted phosphinic acid, each based on the whole flux.
US Pat. No. 10,557,068

ABRASIVE GRAIN WITH MAIN SURFACES AND SUBSIDIARY SURFACES

Robert Bosch GmbH, Stutt...

1. An abrasive grain comprising:at least two main surfaces; and
at least one subsidiary surface, which is connected by way of a first edge to a first main surface of the at least two main surfaces and is connected by way of a second edge to a second main surface of the at least two main surfaces,
wherein the second main surface does not have any edge in common with the first main surface,
wherein the at least one subsidiary surface includes a first obtuse angle with the first main surface in a region of the first edge and a second obtuse angle with the second main surface in a region of the second edge,
wherein the at least two main surfaces of the abrasive grain are substantially planar and lie on faces of one of an imaginary pyramid, an imaginary frustopyramid, and a tetrahedron, and the at least one subsidiary surface truncates the one of the imaginary pyramid, the imaginary frustopyramid, and the tetrahedron, and
wherein each of the at least two main surfaces has a triangular shape.
US Pat. No. 10,555,531

BIOFILM INHIBITING COMPOSITIONS ENHANCING WEIGHT GAIN IN LIVESTOCK

Akeso Biomedical, Inc., ...

1. An antibiotic-free animal feed product comprising one or more compounds represented by:Fe(III)x((ligand))y   Formula Ior a salt or hydrate thereof, whereinx is an integer value of 1-2,
y is an integer value of 1-3 and
each ligand present is independently a conjugate base of an ?-hydroxy acid selected from citric acid, tartaric acid, lactic acid, glycolic acid, quinic acid, isoleucic acid, valic acid, malic acid, and mandelic acid; or
each ligand is a conjugate base of an amino acid independently selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;
wherein the compound is in an effective amount to reduce enteropathogen load in a mammal or bird and wherein when the ligand is a conjugate base of citric acid, the concentration of the compound is from 0.1 g/kg of feed to 2 g/kg of feed.
US Pat. No. 10,555,532

PLANT GROWTH-PROMOTING BACTERIA AND METHODS OF USE

Spogen Biotech Inc., St....

27. An inoculum for application to plants, plant seeds, or a plant growth medium, wherein the inoculum comprises an effective amount of a bacterial culture, an agriculturally acceptable carrier, and a fungicide, wherein the bacteria in the bacterial culture comprise:(a) Bacillus mycoides strain BT155 (NRRL No. B-50291);
(b) Bacillus mycoides strain EE118 (NRRL No. B-50918);
(c) Bacillus subtilis strain EE148 (NRRL No. B-50927);
(d) Alcaligenes faecalis strain EE107 (NRRL No. B-50920);
(e) Bacillus mycoides strain EE141 (NRRL No. B-50916);
(f) Bacillus mycoides strain BT46-3 (NRRL No. B-50922);
(g) Bacillus cereus family member strain EE128 (NRRL No. B-50917);
(h) Bacillus thuringiensis strain BT013A (NRRL No. B-50924);
(i) Paenibacillus massiliensis strain BT23 (NRRL No. B-50923);
(j) Bacillus cereus family member strain EE349 (NRRL No. B-50928);
(k) Bacillus subtilis strain EE218 (NRRL No. B-50926);
(l) Bacillus megaterium strain EE281 (NRRL No. B-50925);
(m) salt-tolerant and thiram-resistant Paracoccus sp. strain NC35 (NRRL No. B-50948);
(n) salt-tolerant and thiram resistant Bacillus mycoides strain BT155 (NRRL No. B-50949);
(o) thiram-resistant Bacillus aryabhattai strain CAP53 (NRRL No. B-50946);
(p) thiram-resistant Bacillus thuringiensis strain BT013A (NRRL No. B-50947); or
(q) glyphosate-tolerant Bacillus aryabhattai strain CAP53 (NRRL No. B-50945);
and wherein the fungicide comprises a substituted benzene, a thiocarbamate, an ethylene bis dithiocarbamate, a thiophthalidamide, a copper compound, an organomercury compound, an organotin compound, a cadmium compound, anilazine, benomyl, cyclohexamide, dodine, etridiazole, iprodione, metlaxyl, thiamimefon, triforine, or a combination thereof.
US Pat. No. 10,557,070

HEAT TRANSFER FLUIDS AND CORROSION INHIBITOR FORMULATIONS FOR USE THEREOF

PRESTONE PRODUCTS CORPORA...

1. A heat transfer fluid concentrate comprising:greater than 90 weight percent of a freezing point depressant;
16 to 80 ppm of magnesium ions;
an azole compound;
an inorganic phosphate;
a carboxylate; and
an acrylate based polymer;
wherein the weight ratio of acrylate based polymer to magnesium ions is 1 to 25;
wherein nitrate, if present, is present in an amount of less than 50 ppm based on total weigh of the heat transfer fluid concentrate;
wherein the heat transfer fluid concentrate has a pH of 7 to 9.5; and
wherein the heat transfer fluid concentrate is free from silicate, borate and amines.
US Pat. No. 10,555,533

SELECTION AND USE OF COLD-TOLERANT BACILLUS STRAINS AS BIOLOGICAL PHYTOSTIMULATORS

ABITEP GmbH, Berlin (DE)...

1. A method of stimulating the growth of cultivated plants, comprising treating said plants with a cold-tolerant Bacillus strain, wherein the cold-tolerant Bacillus strain comprises a Bacillus atrophaeus species and a Bacillus simplex species, and wherein the cold-tolerant Bacillus simplex species comprises ABI02S1 DSM 32020 or ABI12 DSM 32283, or a mixture thereof.
US Pat. No. 10,556,815

COMPOSITIONS FOR MITIGATING HYDROGEN SULFIDE CONTAMINATION USING A RECOMBINANT PROTEIN WITH AN AFFINITY TAG FUSED TO A HYDROGEN SULFIDE SCAVENGING ENZYME

BAKER HUGHES, A GE COMPAN...

1. A recombinant protein, comprising: an affinity tag configured to attach the recombinant protein to a silicate surface, fused to a hydrogen sulfide scavenging enzyme, wherein the recombinant protein comprises the protein having the amino acid sequence set forth in SEQ ID NO: 1.
US Pat. No. 10,555,534

FUSION PROTEINS AND METHODS FOR STIMULATING PLANT GROWTH, PROTECTING PLANTS FROM PATHOGENS, AND IMMOBILIZING BACILLUS SPORES ON PLANT ROOTS

Spogen Biotech Inc., St....

1. A recombinant Bacillus cereus family member that expresses a fusion protein, wherein the fusion protein comprises:a targeting sequence or exosporium protein that is capable of targeting the fusion protein to the exosporium of the recombinant Bacillus cereus family member; and
at least one plant growth stimulating protein or peptide, wherein the plant growth stimulating protein or peptide comprises a chitosanase, a protease, a phosphatase, a nitrogenase, a nuclease, a glucosidase, a flagellin protein, or a flagellin peptide.
US Pat. No. 10,555,535

PEST CONTROL COMPOSITION AND PEST CONTROL METHOD

SUMITOMO CHEMICAL COMPANY...

1. A composition for controlling pests comprising a synergistic effective amount of Bacillus strain APM-1 deposited under ATCC Accession No. PTA-4838 and one or more nicotinic acetylcholine receptor agonist compound selected from the group consisting of clothianidin, flupyradifurone, imidacloprid, thiacloprid and thiamethoxam,wherein the composition comprises the nicotinic acetylcholine receptor agonist compound in the amount of 10?4 to 102 g per 1010 cfu of Bacillus strain APM-1, and
wherein the pests are Hemipteran pests, Lepidopteran pests, Thysanopteran pests, Dipteran pests, or Coleopteran pests.
US Pat. No. 10,557,074

METHODS OF CEMENTING A WELLBORE WITH THE USE OF AN OIL SWELLABLE ELASTOMER

BAKER HUGHES, A GE COMPAN...

1. A method of cementing a wellbore penetrating a subterranean formation, the method comprising:injecting into the wellbore an oil-based fluid;
injecting into the wellbore a cement spacer fluid comprising an aqueous carrier, an oil swellable elastomer, and a viscosifier, the oil swellable elastomer comprising styrene ethylene butadiene styrene, and the viscosifier comprising diutan gum;
contacting the oil-based fluid with the cement spacer fluid to swell the oil swellable elastomer in the cement spacer fluid;
injecting a cement slurry into the wellbore; and
allowing the cement slurry to set,
wherein the cement spacer fluid comprises about 0.5 to about 24 pounds of the oil swellable elastomer per gallon of the cement spacer fluid; and
the weight ratio of the oil-swellable elastomer to the viscosifier is about 95:5 to about 90:10.
US Pat. No. 10,555,537

COMPOSITION FOR LOW-GLUTEN AND LOW-CARBOHYDRATE BAKED AND PASTRY GOODS

1. A composition for preparing bread and bread-like products, wherein the bread-like products are selected from the group consisting of hot dog rolls, hamburger rolls, crispbread, hard-baked rolls, pastries, biscuits pie crusts, pizza crusts, muffins, crackers and wraps, which comprises components a), b) and c) as follows:a) flour obtained from one or more shell fruits and/or oil seeds of non-legumes, in an amount of from 20 to 80% by weight, based on dry matter of the components a), b) and c), wherein the flour comprises at least one partially deoiled flour, having a fat content of less than 30% by weight, in an amount of at least 20% by weight, based on the total weight of the flour,
b) a mucilaginous polysaccharide-comprising plant product or mucilaginous polysaccharides isolated from said plant products in an amount of from 5 to 40% by weight, based on dry matter of the components a), b) and c), and
c) a protein component that is selected from eggs, egg white and egg products, wherein the egg products are selected from whole egg powder and egg white powder, in an amount of from 4 to 40% by weight, based on dry matter of the components a), b) and c),
wherein the component a) comprises a maximum of 75% by weight of component a) of coconut flour,
wherein the fraction of the total amount of the components a), b) and c) of the composition, in each case calculated as dry matter of the components a), b) and c), of the total dry matter of the composition is at least 60% by weight,
wherein the composition comprises less than 15% of soy products, based on the total amount of the dry components of the composition, and
wherein the composition comprises a maximum of 0.1% by weight of gluten.
US Pat. No. 10,556,819

METHOD FOR PREPARING GLASS-CERAMICS, CAPABLE OF ADJUSTING MACHINABILITY OR TRANSLUCENCY THROUGH CHANGE IN TEMPERATURE OF HEAT TREATMENT

HASS CO., LTD, Gangneung...

1. A method for preparing a glass-ceramics containing a silica crystalline phase, the method comprising:performing a first heat treatment on a glass composition at a temperature of 480 to 800° C., so that a lithium disilicate crystalline phase and a silica crystalline phase each having a size of 30 to 500 nm are formed through the first heat treatment; and
performing a second heat treatment at a temperature of 780 to 880° C., so that translucency of the glass ceramics is adjusted based on the temperature of the second heat treatment,
wherein the glass composition comprises:
60 to 83 wt % SiO2;
10 to 15 wt % Li2O;
2 to 6 wt % P2O5 working as a nuclei formation agent;
1 to 5 wt % Al2O3 for increasing a glass transition temperature and a softening point and enhancing chemical durability of glass;
0.1 to 3 wt % SrO for increasing the softening point of the glass;
0.1 to 2 wt % ZnO;
1 to 5 wt % colorants; and
2.5 to 6 wt % mixture of Na2O and K2O for increasing a thermal expansion coefficient of the glass,
wherein the lithium disilicate crystalline phase and the silica crystalline phase each have a transmittance of 18 to 55% at a wavelength of 550 nm, and have a first translucency value at a temperature of 780 to 820° C., a second translucency value at a temperature of 821 to 840° C., a third translucency value at a temperature of 841 to 860° C., and a fourth translucency value at a temperature of 861 to 880° C. depending on the temperature of the second heat treatment,
wherein the translucency values satisfy the following expression 1:
HT>MT>LT>MO
where HT is the first translucency value, MT is the second translucency value, LT is the third translucency value, and MO is the fourth translucency value, and
wherein a retention time is 1 minute to 2 hours.
US Pat. No. 10,555,795

COLORED TRANSLUCENT ZIRCONIA SINTERED BODY AND POWDER, AND USE THEREOF

TOSOH CORPORATION, Yamag...

1. A zirconia powder composition comprising greater than 4.0 mol % and not greater than 6.5 mol % of yttria, less than 0.25 mol % of erbia, greater than 0 ppm and less than 2,000 ppm of iron compound in terms of Fe2O3, less than 0.01 wt. % of cobalt compound in terms of CoO, and less than 0.1 wt. % of alumina; the zirconia powder composition having a BET specific surface area of from 7 to 13 m2/g.
US Pat. No. 10,557,077

OIL-BASED COMPOSITIONS FOR DISPERSING ASPHALTENES AND PARAFFINS

1. An oil based composition, comprising from 0.01 to 1.0 wt % of bismuth nanoparticles; from 90 to 99 wt % of a fatty acid methyl ester non-polar solvent; and an organic acid.
US Pat. No. 10,557,078

BRINE RESISTANT SILICA SOL

NISSAN CHEMICAL AMERICA C...

1. A method of recovering hydrocarbon from subterranean formation, comprisinga) introducing to the subterranean formation a fluid comprising a brine resistant aqueous silica sol, wherein the brine resistant aqueous silica sol comprises silica particles surface functionalized with a polysiloxane oligomer comprising
a monomeric unit of glycidoxypropyltrimethoxysilane and
a monomeric unit selected from the group consisting of phenyltrimethoxysilane, methacryloxypropyltrimethoxysilane, isobutyltrimethoxysilane, vinyltrimethoxysilane, 2-(7-oxabicyclo[4.1.0]hept-3-yl)ethyltrimethoxysilane, and hexamethyldisiloxane;
wherein the silica particles have an average diameter of between about 1 nm and about 100 nm, and
wherein the brine resistant aqueous silica sol is stable to brine exposure under at least two of the tests selected from the group consisting of
1) API Brine by Visual Observation,
2) Artificial Seawater by Visual Observation, and
3) API Brine Resistance Test by use of a Turbidimeter,
wherein under the test of API Brine by Visual Observation or Artificial Seawater by Visual Observation, a stable aqueous silica sol does not become visibly hazy and opaque or undergo gelation at 10 minutes or 24 hours after brine exposure; and
wherein under the test of API Brine Resistance Test by use of a Turbidimeter, a stable aqueous silica sol does not have a change in turbidity of more than 100 Nephelometric Turbidity Units at 24 hours after brine exposure compared to initial turbidity after brine exposure,
wherein the monomeric unit of glycidoxypropyltrimethoxysilane and monomeric unit of phenyltrimethoxysilane, exhibit a critical surface tension in the range of from about 40 mN/m to about 50 mN/m; and
wherein the methacryloxypropyl trimethoxysilane, isobutyl trimethoxysilane, vinyltrimethoxysilane, 2-(7-oxabicyclo[4.1.0]hept-3-yl)ethyltrimethoxysilane and hexamethyldisiloxane; exhibit a critical surface tension in the range of from about 15 mN/m to about 39.5 mN/m; and
b) recovering the hydrocarbon from the subterranean formation.
US Pat. No. 10,555,541

METHOD FOR PRODUCING A DAIRY PRODUCT

1. A polypeptide having transgalactosylating activity, which is a truncated polypeptide consisting of the amino acid sequence of amino acids 28-979 of SEQ ID NO: 1 or is a fragment thereof having transgalactosylating activity, wherein the polypeptide is isolated.
US Pat. No. 10,555,543

CONFECTIONERY PRODUCTS WITH PEA PROTEINS

Roquette Freres, Lestrem...

1. A confectionery traditionally made with milk comprising Maillard reacted proteins and reducing carbohydrates, said proteins include at least 0.5% to 30% of pea proteins in dry weight, relative to the total dry weight of the confectionery, and 0.5% to 30% of milk proteins by weight, relative to the total weight of the confectionery, wherein the confectionery traditionally made with milk at least maintains organoleptic properties of a milk only confectionery, wherein the confectionery is selected from the group consisting of soft or hard caramels, toffees and fudges, wherein the residual moisture of said confectionery varies between 3 to 10%.
US Pat. No. 10,555,544

DELIVERY OF ACTIVE AGENTS USING A CHOCOLATE VEHICLE

Lesaffre Yeast Corporatio...

1. A confectionary composition comprising:a fat matrix comprising both a non-cocoa hard butter and cocoa butter, said fat matrix having a melting point between about 33° C. and about 49° C.; and
at least about 20% by weight of one or more minerals in particulate form, having a median particle size between about 1 ?m and about 25 ?m, and being insoluble in said fat matrix, said one or more minerals being homogeneously dispersed throughout said fat matrix and having a particle size distribution with a full-width at half maximum (FWHM) of at least about 5% of the median particle size, wherein said confectionary composition has an apparent viscosity in the molten state within about ±50% of the apparent viscosity of said fat matrix in the absence of said one or more minerals, as measured under conditions of identical temperature and shear.
US Pat. No. 10,556,828

METHOD OF SIZING OF FIBERS AND ARTICLES MANUFACTURED FROM THE SAME

Oxford Performance Materi...

1. A method of applying a sizing composition to a target material, the method comprising the steps of:functionalizing a polyetherketoneketone (PEKK) polymer by sulfonation to form sPEKK;
combining the sPEKK with water to form a sizing composition;
applying the sizing composition to the target material;
heating the sizing composition applied to the target material to at least 150° C. to evaporate the water in the applied sizing composition,
wherein the applied sizing composition applied to the target material is water soluble after the step of heating to evaporate.
US Pat. No. 10,556,829

CEMENT SLURRIES, CURED CEMENT AND METHODS OF MAKING AND USE OF THESE

Saudi Arabian Oil Company...

1. A cement slurry comprising:water;
a cement precursor material; and
a block copolymer composition having at least one copolymer backbone, each copolymer backbone comprising at least two hard segments, and a soft segment disposed between the at least two hard segments, in which the copolymer backbone has at least one anhydride group grafted onto the soft segment, and in which the anhydride group is crosslinked by an aminosilane crosslinker.
US Pat. No. 10,557,085

PHOTOALIGNMENT COMPOSITION

ROLIC AG, Zug (CH)

1. A photoalignment composition comprisinga) at least a single photoalignment polymer, and
b) at least a single solvent of formula (I)
(R—CO—O—R?),
wherein R and R? are independently from each other a straight-chain alkyl, or branched alkyl chain; with the proviso that at least one alkyl chain is branched.
US Pat. No. 10,556,830

LOW-DENSITY HIGH-STRENGTH CONCRETE AND RELATED METHODS

Sebastos Technologies Inc...

1. A lightweight concrete composition comprising:one or more cementitious materials;
an aggregate mix composed of individual particles that are substantially volumetrically stable and non-absorbent;
said aggregate mix comprising hollow glass microspheres;
an air detrainer;
a shrinkage reducer;
and a viscosity modifier;
wherein the lightweight concrete composition has a compressive strength after 28 days as measured by ASTM C39 of at least about 1750 psi.
US Pat. No. 10,556,831

METHOD OF MANUFACTURING CERAMIC MATRIX COMPOSITE OBJECTS

MBDA UK Limited, Stevena...

1. A method of manufacturing a ceramic matrix composite object comprising the steps of:(i) providing a first arrangement of one or more fibre plies, and machining the first arrangement to a predetermined configuration to form a first preform;
(ii) providing a second arrangement of one or more fibre plies, and machining the second arrangement to a predetermined configuration to form a second preform;
(iii) wrapping the second preform around at least one edge of the first preform;
(iv) fixing the first and second preforms together to form a combined first and second preform;
(v) providing one or more further arrangements of one or more fibre plies, machining the one or more further arrangements to a predetermined configuration to form one or more further preforms; and successively adhering each of the one or more further preforms to the combined first and second preform to form a complete preform in which at least one of the one or more further preforms are wrapped around one of the first, second, or one or more further preforms; and
(vi) rigidizing the complete preform by a step comprising infiltrating the combined first and second preforms with a liquid material, the liquid material selected to react with a component of the first and second preforms so as to form a ceramic.
US Pat. No. 10,559,392

SYSTEM AND METHOD FOR CONTROLLING PARTICLES USING PROJECTED LIGHT

Wisconsin Alumni Research...

1. A system for controlling particles using projected light, the system comprising:a particle system configured to provide a plurality of particles;
an optical source configured to generate a beam of light with a frequency shifted from an atomic resonance of the plurality of particles; and
a beam filter positioned between the particle system and plurality of particles, and comprising a first mask, a first lens, a second mask, and a second lens,
wherein the optical source, beam filter, and particle system are arranged such that the beam of light from the optical source passes through the beam filter, and is projected on the plurality of particles to form an optical pattern that controls the positions of the particles in space.
US Pat. No. 10,555,550

TOPICAL FLAVOURING COMPOSITIONS COMPRISING OLEIC ACID AND SODIUM OLEATE

Givaudan, S.A., Vernier ...

1. A method of applying to the surface of a comestible product a solid flavouring, comprising dispersion of the solid flavouring in a non-aqueous continuous medium in the presence of oleic acid and sodium oleate and its topical application to the product, the weight ratio of oleic acid to sodium oleate being from 80:20-54:46.
US Pat. No. 10,557,856

BIOMARKERS OF RENAL INJURY

University Of Pittsburgh-...

1. A method for predicting dialysis independence after an acute renal injury, comprising:a) initiating renal replacement therapy in a patient having an acute renal injury, wherein said patient does not have an end stage renal disease;
b) collecting at least two urine samples from said patient within fourteen days of said initiating renal replacement therapy;
c) introducing said at least two urine samples into an assay device that detects a hyaluronic acid value normalized to urinary creatinine content in said urine sample, wherein said hyaluronic acid level decreases between an earlier urine sample hyaluronic acid value and a later urine sample hyaluronic acid level; and
d) calculating therefrom an area under the curve receiver operated characteristic (AUC ROC) determination patient value between said earlier and later urine sample hyaluonic acid levels;
e) correlating said AUC ROC patient value to an AUC ROC predetermined threshold value to determine a probability of recovery versus non-recovery for said patient;
f) predicting a recovery of said patient when said probability of recovery vesus non-recovery correlates said AUC ROC patient value at or above said AUC ROC predetermined threshold value; and
g) removing said patient from said renal replacement therapy under conditions of dialysis independence.
US Pat. No. 10,557,858

BIOMARKERS FOR RISK PREDICTION OF MORTALITY

Roche Diagnostics Operati...

1. A method for predicting the risk of a human subject of progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or of death, said method comprising:(a) detecting in said human subject the presence of abnormal midwall fractional shortening (abnormal MFS) using echocardiography,
(b) measuring the level of at least one biomarker from a blood, serum or plasma sample of the human subject, said biomarker(s) selected from the group consisting of B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), Growth Differentiation Factor 15 (GDF-15), Intercellular Adhesion Molecule 1 (ICAM-1) and Angiopoietin-2 (ANG2) in a sample from the subject,
(c) comparing the level of said at least one biomarker to a reference level, and
(d) predicting the risk of a subject of progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or of deathwherein said subject does not suffer from left ventricular hypertrophy, andwherein a level of the at least one biomarker above the reference level indicates that the subject is at risk of progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or of death, or wherein a level of the at least one biomarker below the reference level indicates that the subject is not at risk of progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or of death.
US Pat. No. 10,556,835

METHOD FOR POST-PROCESSING COLORED ZIRCONIUM OXIDE CERAMIC

LIAONING UPCERA DENTAL CO...

1. A method for post-processing a colored 3Y-TZP zirconium oxide ceramic, the method comprising:putting the colored 3Y-TZP zirconium oxide ceramic along with a deoxidant into a heating device; and
performing a firing process at a preset temperature,
wherein the colored 3Y-TZP zirconium oxide ceramic is obtained by coloring a 3Y-TZP zirconium oxide ceramic with a colorant containing Pr3+,
wherein the amount of said deoxidant is over-stoichiometric with respect to the amount of oxygen present in said heating device, and
wherein the colored 3Y-TZP zirconium oxide ceramic is produced to be a dental prosthesis, and a color of the dental prosthesis is a tooth color of patients.
US Pat. No. 10,557,859

ASTROCYTE TRAUMATOME AND NEUROTRAUMA BIOMARKERS

THE REGENTS OF THE UNIVER...

1. A method for detection and treatment of traumatic brain injury (TBI) in a subject, the method comprising:(a) contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI, wherein the marker of TBI comprises aldolase C (ALDOC), or a trauma-specific break down product (BDP) of ALDOC, wherein the trauma-specific BDP of ALDOC is selected from the group consisting of a 38 kDa fragment, a 35 kDa fragment, a 30 kDa fragment, and a 23 kDa fragment;
(b) measuring the amount of marker present in the specimen as compared to a control sample;
(c) determining the presence of an elevated amount of the marker in the specimen compared to the control sample; and
(d) treating the subject for TBI when the specimen is determined to have an elevated amount of the marker.
US Pat. No. 10,557,860

CIRCULATING PULMONARY HYPERTENSION BIOMARKER

The Johns Hopkins Univers...

1. A method for predicting or diagnosing pulmonary artery hypertension (PAH) in a subject having PAH, at risk of having PAH, or suspected of having PAH, the method comprising:(a) contacting a sample from a subject at risk of having or suspected of having PAH with an antibody bound to a substrate, wherein the antibody specifically binds SEQ ID NO:1;
(b) detecting an elevated level of expression of Hepatoma Derived Growth Factor (HDGF) relative to a control with a monoclonal antibody that specifically binds HDGF, wherein the detection is indicative that the subject has or is susceptible to developing PAH.
US Pat. No. 10,557,861

SYSTEMS, METHODS, AND BIOMARKERS FOR DETERMINING THE METABOLIC STATE OF RED BLOOD CELLS AND PLATELETS

UNIVERSITY OF ICELAND, CE...

1. An analytical storage device comprising:a storage container configured to store a composition comprising red blood cells (RBCs) and an additive solution;
a test portion comprising a test label, the test portion mechanically coupled to the storage container, the test label comprising:
(a) a testing module comprising a detector comprising reagents and configured to carry out a test reaction of the RBCs with the reagents to detect a metabolic state of red blood cells (RBCs) as indicated by a concentration of one or more biomarkers of the metabolic state of RBCs selected from the group consisting of hypoxanthine, inosine, adenine, glucose, lactate, Na+, K+, and pyruvate, wherein the hypoxanthine and adenine are extracellular; and
(b) an analytical module configured to assign one phase out of three possible phases to the RBC sample indicative of the metabolic state of the RBCs and based on the concentration of the one or more biomarkers of the metabolic state of RBCs, the three possible phases comprising:
(i) a First Phase when a comparison of a measured ratio of glucose:lactate and a ratio of Na+:K+matches the values of an RBC control having predetermined values indicated for the metabolic state of the RBCs for the First Phase; and optionally, when one or more of a concentration of inosine, a ratio of hypoxanthine:adenine, a ratio of inosine:adenine, and a concentration of pyruvate, match values of the RBC control having predetermined values indicated for the metabolic state of the RBCs for First Phase;
(ii) a Second Phase when the ratio of hypoxanthine:adenine matches a value of an RBC control having predetermined values indicated for the metabolic state of the RBCs for the Second Phase; and optionally when the concentration of inosine and/or the ratio of inosine:adenine matches values of the RBC control having predetermined values indicated for the metabolic state of the RBCs for Second Phase; and
(iii) a Third Phase when the concentration of hypoxanthine or the ratio of hypoxanthine:adenine, matches values of an RBC control having predetermined values indicated for the metabolic state of the RBCs for the Third Phase; and optionally when one or more of the concentration of adenine, pCO2:pH, the ratio of inosine:adenine and the concentration of inosine match values of the RBC control having predetermined values indicated for the metabolic state of the RBCs for the Third Phase; and
an indicator operably connected to the test portion comprising the test label and configured to (i) receive, from the analytical module of the test label, the assigned phase and (ii) display the phase.
US Pat. No. 10,556,839

METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITS

Pivot Bio, Inc., Berkele...

1. A method of increasing an amount of atmospheric derived nitrogen in a corn plant in a field, the method comprising:exposing a corn plant in a field to a plurality of engineered diazotrophs comprising at least one genetic variation introduced in a nitrogen fixation genetic regulatory network that increases expression or activity of nifH, wherein the at least one introduced genetic variation comprises genetic material that originates from at least one organism of the same genus as said plurality of engineered diazotrophs,
whereby the corn plant exposed to the engineered diazotrophs comprises an increased amount of atmospheric derived nitrogen relative to a corn plant exposed to the same amount of non-engineered diazotrophs of the same species as the engineered diazotrophs.
US Pat. No. 10,558,119

COMPOSITION FOR COATING RESIST PATTERN

NISSAN CHEMICAL INDUSTRIE...

1. A composition for applying to a resist pattern comprising:a component (A), which is at least one compound selected from the group consisting of a metal oxide (a1), a polyacid (a2), a polyacid salt (a3), a hydrolyzable silane (a4), a hydrolysis product (a5) of the hydrolyzable silane, and a hydrolysis condensate (a6) of the hydrolyzable silane; and
a component (B), which is an aqueous solvent,
wherein
the metal oxide (a1) is an oxide of titanium, zirconium, aluminum, or hafnium,
the polyacid (a2) is an isopolyacid selected from molybdic acid or is a heteropolyacid selected from phosphomolybdic acid,
the polyacid salt (a3) is an ammonium salt of an isopolyacid selected from molybdic acid or an ammonium salt of a heteropolyacid selected from phosphomolybdic acid, and
the hydrolyzable silane (a4) is (i) a hydrolyzable silane containing an organic group having an amino group, (ii) a hydrolyzable silane containing an organic group having an ionic functional group, (iii) a hydrolyzable silane containing an organic group having hydroxy group, or (iv) a hydrolyzable silane containing an organic group having a functional group convertible to hydroxy group.
US Pat. No. 10,557,096

COPOLYMER AND USE THEREOF FOR REDUCING CRYSTALLIZATION OF PARAFFIN CRYSTALS IN FUELS

BASF SE, Ludwigshafen (D...

1. A copolymer, obtained by copolymerization of(A) at least one unsaturated dicarboxylic acid or a derivative thereof,
(B) at least one ?-olefin having from at least 6 up to and including 20 carbon atoms,
(C) at least one C3- to C20-alkyl ester of acrylic acid or methacrylic acid or a mixture thereof and
(D) optionally one or more further copolymerizable monomers other than monomers (A), (B) and (C),
followed by reaction with at least one dialkylamine (E), where two alkyl radicals in the at least one dialkylamine (E) are independently alkyl radicals having at least 17 up to 30 carbon atoms.
US Pat. No. 10,558,122

COMPOSITIONS COMPRISING SULFONAMIDE MATERIAL AND PROCESSES FOR PHOTOLITHOGRAPHY

Rohm and Haas Electronic ...

1. A method for processing a photoresist composition, comprising:(a) applying on a substrate a photoresist composition to form a photoresist layer, wherein the photoresist composition comprises:
(i) one or more resins,
(ii) a photoactive component, and
(iii) one or more polymers that comprise:
1) a group of the formula RS(?O)2(X)NR?2 where X is a 1 to 8 carbon linkage, R is a non-hydrogen substituent, and each R? is independently a hydrogen or non-hydrogen substituent, and
2) one or more photoacid-labile groups wherein the iii) one or more polymers are different from the one or more resins; and
(b) immersion exposing the photoresist layer to radiation activating for the photoresist composition.
US Pat. No. 10,557,099

OIL BASED PRODUCT FOR TREATING VANADIUM RICH OILS

General Electric Company,...

1. An oil-based fuel additive composition for use in a vanadium-containing ash bearing fuel, the composition comprising:an oil-based carrier solvent;
a first inhibitor and a second inhibitor that each, when combusted with the vanadium-containing ash bearing fuel in a combustion apparatus, retard vanadium corrosion resulting from combustion of the fuel in the combustion apparatus, wherein the first and second inhibitors are each dispersed in the oil-based carrier solvent, and wherein the first and second inhibitors each, independently, comprise a rare earth element compound, an alkaline earth element compound, or a combination thereof;
a third inhibitor dispersed in the oil-based carrier solvent that retards combustion-related contaminant corrosion in the combustion apparatus, wherein the third inhibitor comprises a non-vanadium first row transition metal or main group metal compound;
a fourth inhibitor dispersed in the oil-based carrier solvent that retards non-combustion related corrosion;
an asphaltene dispersant dispersed in the oil-based carrier solvent;
a combustion additive dispersed in the oil-based carrier solvent that improves combustion of the fuel; and
a stabilizer that stabilizes dispersion of the first inhibitor, the second inhibitor, the third inhibitor, the fourth inhibitor, the asphaltene dispersant, and/or the combustion additive in the oil-based carrier solvent,
wherein the oil-based fuel additive composition is comprised of 10-30 wt % of the first inhibitor, the second inhibitor, the third inhibitor, the fourth inhibitor, the asphaltene dispersant, the combustion additive, and the stabilizer with the remainder comprised of oil-based carrier solvent.
US Pat. No. 10,559,406

DATA COMMUNICATION CABLE HAVING MODIFIED DELAY SKEW

General Cable Technologie...

1. A communication cable comprising:a cable core comprising:
a first twisted wire pair having a first lay length and comprising two insulated wires; and
a second twisted wire pair having a second lay length, the second lay length being shorter than the first lay length;
wherein the two insulated wires of the first twisted wire pair each comprise a insulation layer formed of a fluoropolymer and a propagation speed modifier;
wherein the propagation speed modifier comprises titanium dioxide; and
wherein the insulation layer of each of the two insulated wires of the first twisted wire pair comprise about 0.2% to about 0.45%, by weight, of the propagation speed modifier; and
a jacket layer surrounding the cable core;
wherein the communication cable exhibits a delay skew of about 45 nanoseconds or less over a cable length of 100 meters.
US Pat. No. 10,557,102

LUBRICANT FOR MARINE ENGINES

TOTAL MARKETING SERVICES,...

1. A lubricant composition for marine engines, comprising:at least 40% by weight of lubricant base oil,
at least one fatty amine of formula (I):
R1R2N—(CH2)3—[NH(CH2)3]n—NH2   (I)
wherein:
R1 represents a saturated, linear or branched alkyl group comprising at least 14 carbon atoms,
R2 represents a saturated, linear or branched alkyl group comprising at least 14 carbon atoms,
n represents 0, 1 or 2,
the fatty amine having a BN determined according to standard ASTM D-2896 ranging from 150 to 350 milligrams of potassium hydroxide per gram of amine, and
at least 3% by weight of overbased detergent and/or neutral detergent relative to a total weight of the composition, the overbased and/or neutral detergent selected so that a BN provided by the overbased and/or neutral detergent represents a contribution of greater than 40 mg KOH/g of lubricant,
wherein a mass percentage of fatty amine of formula (I) relative to the total weight of the lubricant composition is from 0.1 to 15% and is chosen so that a BN provided by the fatty amine of formula (I) represents a contribution of from 5 to 30 milligrams of potassium hydroxide per gram of lubricant, and
said lubricant composition having a BN determined according to standard ASTM D-2896 of at least 74 milligrams of potassium hydroxide per gram of lubricant composition and a kinematic viscosity measured according to standard ASTM D445 at 100° C. ranging from 12.5 to 26.1 cSt.
US Pat. No. 10,559,407

PROCESS FOR PRODUCING ELECTRICAL WIRE MOLDED BODY

Riken Technos Corporation...

1. A process for producing an electrical wire molded body comprising:melting and kneading 30 parts to 100 parts by weight of component (a): a polyethylene-based resin, 0 part to 40 parts by weight of component (b): a polypropylene-based resin, 0 part to 40 parts by weight of component (c): a block copolymer of an aromatic vinyl-based compound and a conjugated diene-based compound and/or a hydrogenated product thereof, 5 parts to 15 parts by weight of component (d): an acid-modified resin and 0 part to 30 parts by weight of component (e): a non-aromatic softening agent for rubber (provided that the total amount of the components (a), (b), (c), (d) and (e) is defined as 100 parts by weight), and 0.2 parts to 0.6 parts by weight of component (f): an organic peroxide, 1 part to 6 parts by weight of component (g): a silane coupling agent and 50 parts to 250 parts by weight of component (h): a metal hydrate based on 100 parts by weight of the total amount of the components (a), (b), (c), (d) and (e), all at once, at a temperature equal to or higher than the reaction temperature of the component (f): organic peroxide, to react the resin component comprising (a) to (e) with the silane coupling agent (g) thereby producing component (A) which is a silane crosslinkable flame retardant polyolefin comprising a reactant of the resin component with the silane coupling agent;
melting and kneading 100 parts by weight of at least one polymer selected from the group consisting of the components (a), (b) and (c) and 0.1 part to 8 parts by weight of component (i): a silanol condensation catalyst, to produce component (B), which is a silanol catalyst resin composition; and
mixing the components (A) and (B) in a ratio of (A):(B)=10:1 to 100:1 (weight ratio) to form a mixture, melt molding the mixture on a conductor to form a molded body and then crosslinking the molded body in the presence of water.
US Pat. No. 10,557,103

REFRIGERATOR LUBRICATING OIL AND MIXED COMPOSITION FOR REFRIGERATOR

IDEMITSU KOSAN CO., LTD.,...

1. A refrigerator lubricating oil, comprising:a base oil comprising, as a major component, a polyol ester (A) of a fatty acid (art) having a number of carbon atoms of from 3 to 18 and a polyol (a2) that is at least one selected from the group consisting of neopentyl glycol, trimethylolethane, trimethylolpropane, trimethylolbutane, pentaerythritol, and dipentaerythritol; and
a disulfide compound (B) and a trisulfide compound (B), blended in an amount of from 30 to 10,000 ppm by mass in terms of sulfur equivalent based on a total amount of the refrigerator lubricating oil,
wherein the disulfide compound (B) and the trisulfide compound (B) are represented by formula (2):
R1—Sn—R2  (2),
wherein:
R1 and R2 are each independently a hydrocarbon having a number of carbon atoms of from 1 to 4; and
n is 2 in the disulfide compound (B) and n is 3 in the trisulfide compound (B).
US Pat. No. 10,558,129

MASK ASSEMBLY

ASML Netherlands B.V., V...

1. A mask assembly suitable for use in a lithographic process, the mask assembly comprising:a patterning device; and(a) a pellicle frame configured to support a pellicle and mounted on the patterning device with a mount;(b) wherein the mount is configured to suspend the pellicle frame relative to the patterning device such that there is a gap between the pellicle frame and the patterning device; andwherein the mount provides a releasably engageable attachment between the patterning device and the pellicle frame.
US Pat. No. 10,556,850

PROCESS FOR THE PURIFICATION OF ACROLEIN

Evonik Degussa GmbH, Ess...

1. A process for purifying acrolein, the process comprisinga) splitting a liquid feed stream comprising acrolein into at least a first liquid stream and a second liquid stream,
b) introducing the first liquid stream with a temperature T1 into a distillation column at a point between the top and the bottom of the distillation column,
c) introducing the second liquid stream with a temperature T2 into the distillation column at the top of the distillation column,
d) withdrawing an overhead vapor stream enriched in acrolein from the distillation column, and
e) withdrawing a bottom stream depleted in acrolein from the distillation column,
wherein the temperature T2 of the second liquid stream in said introducing c) is lower than the temperature T1 of the first liquid stream in said introducing b).
US Pat. No. 10,557,107

POST CHEMICAL MECHANICAL POLISHING FORMULATIONS AND METHOD OF USE

ENTEGRIS, INC., Billeric...

1. A cleaning composition comprising at least one quaternary base present in an amount ranging from about 6% to about 10% by weight, at least one organic amine present in an amount ranging from about 1% to about 7% by weight, at least one corrosion inhibitor present in an amount ranging from about 0.05% to about 0.3% by weight, at least one complexing agent present in amount ranging from about 1% to 4% by weight, and at least one solvent, wherein the corrosion inhibitor is selected from the group consisting of 4-methylpyrazole, pyrazole, 2-amino-thiazole, 2-amino-1,3,4-thiadiazole, pterine, pyrazine, cytosine, pyridazine, derivatives thereof, and combinations thereof, and wherein the cleaning composition is substantially devoid of alkali hydroxides, alkaline earth metal hydroxides, and tetramethylammonium hydroxide.
US Pat. No. 10,557,110

METAL-CARRYING ZEOLITE FOR ALCOHOLIC BEVERAGES AND ALCOHOLIC BEVERAGE MANUFACTURING METHOD

IDEMITSU KOSAN CO., LTD.,...

1. A method for reducing a storage period during production of an alcoholic beverage, comprising:purifying an alcoholic composition by removing an unwanted component,
wherein the unwanted component is at least one selected from the group consisting of dimethyl sulfide, dimethyl disulfide, and dimethyl trisulfide,
the unwanted component is removed by a metal-supported zeolite comprising silver supported on a zeolite, and
the zeolite is at least one selected from the group consisting of a beta-type zeolite and a Y-type zeolite.
US Pat. No. 10,557,114

THIOESTERASES AND CELLS FOR PRODUCTION OF TAILORED OILS

CORBION BIOTECH, INC., S...

1. A recombinant nucleic acid construct comprising a regulatory element and a FatB gene expressing an active acyl-ACP thioesterase operable to produce an altered fatty acid profile in an oil produced by a cell expressing the nucleic acid construct, wherein the FatB gene expresses a protein having at least 94.6%, 95%, 96%, 97%, 98%, or 99% sequence identity with SEQ ID NOs: 82 or 178, and optionally wherein the fatty acid of the oil is enriched in C8 and C10 fatty acids.
US Pat. No. 10,557,115

MEDIUM CONTAINING URIDINE AND N-ACETYL-D-MANNOSAMINE

JCR Pharmaceuticals Co., ...

1. A cell culture medium, comprising:uridine at a concentration of 0.5 to 10 mM; and
N-acetyl-D-mannosamine at a concentration of 1 to 15 mM.
US Pat. No. 10,557,116

TREATMENT OF LUNG AND PULMONARY DISEASES AND DISORDERS

DePuy Synthes Products, I...

1. A method of reducing vascular leak, edema, or inflammation in a lung of a patient having hyperoxia or acute lung injury comprising systemically administering to the patient an effective amount of umbilical cord tissue-derived cells, wherein the umbilical cord tissue-derived cells are isolated from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a lung tissue, and do not express CD117, hTERT or telomerase, andwherein the levels of keratinocyte factor, gamma interferon-inducible cytokine, interleukin 1-alpha and monocyte chemotactic factor-1 are reduced in the lung of the patient having hyperoxia or acute lung injury.
US Pat. No. 10,555,579

PLASTIC COMPOSITION, MIDSOLE MADE FROM THE SAME AND METHOD OF MAKING

I-Tech. Sporting Enterpri...

1. A plastic composition for producing a plastic product, comprising:a polymer component including an ethylene-vinyl (EVA) copolymer, a first ethylene-?-olefin copolymer having a hardness ranging from 55 Shore A to 60 Shore A measured according to ASTM D2240, a second ethylene-?-olefin copolymer having a hardness ranging from 85 Shore A to 90 Shore A measured according to ASTM D2240, and polypropylene (PP),
wherein the plastic product made from the composition has a loss factor ratio of tan ?(?20° C.) to tan ?(40° C.) at a frequency of 10 Hz, measured according to JIS k 7244-4, ranging from 2.5 to 3.8.
US Pat. No. 10,557,118

COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF NEOPLASTIC DISEASE IN A MAMMALIAN SUBJECT

The Government of the Uni...

1. A method of treating renal cell carcinoma in a mammalian subject, comprising administering to the subject an effective amount of a CD8+ T cell population or dendritic cells specific for a human endogenous retrovirus type E (HERV-E) antigen present on the renal cell carcinoma, wherein the HERV-E antigen comprises a polypeptide encoded by a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 45 or SEQ ID NO: 47.
US Pat. No. 10,556,863

CRYSTALLINE FORM OF (R)-4-HYDROXY-2-OXO-1-PYRROLIDINEACETAMIDE, PREPARATION METHOD THEREFOR AND USE THEREOF

CHONGQING RUZER PHARMACEU...

1. A crystalline form I of (R)-4-hydroxy-2-oxo-1-pyrrolidineacetamide having diffraction peaks at diffraction angles 2? of 16.66±0.2°, 17.54±0.2°, 21±0.2°, 22.16±0.2°, and 30.96±0.2°.
US Pat. No. 10,557,119

ERYTHROID CELLS COMPRISING PHENYLALANINE AMMONIA LYASE

RUBIUS THERAPEUTICS, INC....

1. An enucleated erythroid cell comprising an exogenous polypeptide comprising phenylalanine ammonia lyase (PAL) or a functional fragment thereof,wherein the enucleated erythroid cell is made by a process comprising introducing an exogenous nucleic acid encoding the exogenous polypeptide into a nucleated erythroid cell precursor.
US Pat. No. 10,557,120

OSTEOBLAST AND METHOD FOR PREPARING SAME

KYOTO PREFECTURAL PUBLIC ...

1. A method of generating an osteoblast from a somatic cell of a mammal, the method comprising introducing a reprogramming-related gene or an expression product thereof into the somatic cell, wherein the osteoblast is directly induced from the somatic cell without first becoming an induced pluripotent stem (iPS) cell or an embryonic stem (ES) cell, and wherein the reprogramming-related gene or the expression product thereof to be introduced into the somatic cell consists of one combination selected from the group consisting of Oct4L, Oct4M, and Oct4LM, where M represents “c-Myc” and L represents “L-Myc”.
US Pat. No. 10,557,121

METHOD FOR CHONDROGENIC INDUCTION

Kyoto University, Kyoto ...

1. A method for producing chondrocytes from pluripotent stem cells, the method comprising:(i) culturing pluripotent stem cells under adherent conditions in a medium containing an HMG-CoA reductase inhibitor and one or more substances selected from the group consisting of BMP2, TGF? and GDF5, and
(ii) culturing the cells obtained in step (i) under suspension conditions in a medium containing an HMG-CoA reductase inhibitor and one or more substances selected from the group consisting of BMP2, TGF? and GDF5,
wherein the pluripotent stem cells used in step (i) are in the form of cell clusters produced by a method comprising suspension culture in a medium that allows the pluripotent stem cells to retain their undifferentiated state.
US Pat. No. 10,557,122

MESENCHYMAL-LIKE STEM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS, METHODS AND USES THEREOF

IMSTEM BIOTECHNOLOGY, INC...

1. A method for immunosuppressing T-cells, the method comprising contacting T-cells with an effective dose of human embryonic stem cell derived mesenchymal stem cells (hES-MSCs), wherein said contacting results in immunosuppressing T-cells, and the hES-MSCs are produced by a method comprising the steps of;(a) culturing human embryonic stem cells in a serum free medium comprising at least one GSK3 inhibitor at a concentration ranging from 0.05 pM to 0.2 pM, wherein the human embryonic stem cells are cultured in the absence of feeder cells;
(b) culturing the cells from step a) in a serum-free medium comprising vascular endothelial growth factor (VEGF) and bone morphogenic protein 4 (BMP4) in an amount sufficient to induce formation of embryoid bodies comprising human hemangio-colony forming cells;
(c) adding at least one growth factor to the culture resulting from step b), wherein the growth factor is in an amount sufficient to expand human hemangio-colony forming cells;
(d) disaggregating the hemangio-colony forming cells resulting from step c) into single cells; and
(e) culturing the single hemangio-colony forming cells resulting from step d) in mesenchymal stem cell medium containing serum, knockout serum replacement (KOSR), or in a serum-free medium to induce differentiation of the single cells into human mesenchymal stem cells, wherein at least 90% of the hES-MSCs express CD73, and said hES-MSCs: (i) comprise greater than 95% of cells expressing CD73, CD90, CD105, CD146, CD166, and CD44; (ii) comprise greater than 80% of cells expressing CD13, CD29, CD54, and CD49E; (iii) comprise less than 5% of cells expressing CD45, CD34, CD31 and SSEA4; (iv) express IL-10 and TGF?; (v) comprise less than 2% of cells expressing IL-6, IL-12 and TNF?; and (vi) comprise less than 0.001% of cells coexpressing OCT4, NANOG, TRA-1-60 and SSEA4.
US Pat. No. 10,557,123

METHODS FOR REPROGRAMMING CELLS AND USES THEREOF

Genesis Technologies Limi...

1. A method of obtaining a neural multipotent or unipotent cell, comprising:i) providing a cell of a first type which is not a neural multipotent or unipotent cell;
ii) increasing expression of at least one neural multipotent or unipotent gene regulator in the cell of a first type, to a level at which the at least one neural multipotent or unipotent gene regulator is capable of driving transformation of the cell of a first type into the neural multipotent or unipotent cell, wherein the at least one multipotent or unipotent gene regulator is Musashi1 (Msi1), Neurogenin 2 (Ngn2), or both Msi1 and Ngn2; and
iii) placing or maintaining the cell in a neural cell culture medium and maintaining sufficient intracellular levels of the at least one multipotent or unipotent gene regulator for a sufficient period of time to allow a stable neural multipotent or unipotent cell to be obtained.
US Pat. No. 10,557,124

COMPOSITIONS AND METHODS FOR OBTAINING STEM CELL DERIVED LUNG TISSUE, AND RELATED USES THEREOF

THE REGENTS OF THE UNIVER...

1. A method for obtaining lung organoid tissue, comprising:(a) culturing definitive endoderm cells in vitro and differentiating the definitive endoderm cells into tissue comprising ventral-anterior foregut spheroid tissue by activating a Wnt signaling pathway with CHIR99021 or Wnt, activating an FGF signaling pathway with FGF, inhibiting a BMP signaling pathway with Noggin, and inhibiting a TGF? signaling pathway with SB431542,
(b) culturing the obtained ventral-anterior foregut spheroid tissue in vitro and differentiating the obtained ventral-anterior foregut spheroid tissue into tissue comprising 3-dimensional lung tissue by activating a Hedgehog signaling pathway with smoothened agonist (SAG), and
(c) culturing the obtained 3-dimensional lung tissue in vitro and differentiating the obtained tissue comprising 3-dimensional lung tissue into lung organoid tissue by activating the FGF signaling pathway with FGF 10 to obtain a lung organoid tissue.
US Pat. No. 10,556,357

SPLITTING OF THICK HARD-FOAM PLATES

Evonik Roehm GmbH, Darms...

1. A method for planar division of a rigid foam to obtain a film or thin sheet, said method comprising:flexibilizing the rigid foam to obtain a flexibilized foam, and
cutting the flexibilized foam with a knife,
wherein said flexibilizing of the rigid foam prior to cutting is accomplished by storing the rigid foam in water and/or heating or adjusting to a temperature in a range of from T-15° C. to T-1° C. where T is a foaming temperature of the rigid foam, and
the rigid foam is a PE, PP, PVC, PMMA or P(M)I foam.
US Pat. No. 10,557,126

POLYNUCLEOTIDES ENCODING CYCLOHEXANONE MONOOXYGENASES

Codexis, Inc., Redwood C...

1. A non-naturally occurring polynucleotide encoding a non-naturally occurring polypeptide having cyclohexanone monooxygenase (CHMO) activity wherein the amino acid sequence of the polypeptide has at least 90% sequence identity to SEQ ID NO: 2, and one or more amino acid substitutions at one or more positions corresponding to positions in SEQ ID NO: 2, selected from the group consisting of 75, 79, 82, 99, 110, 166, 172, 208, 216, 273, 324, 364, 395, 412, 491, 503, and 504.
US Pat. No. 10,557,127

CELLOBIOHYDROLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME

1. A cellobiohydrolase variant, comprising a substitution at one or more positions corresponding to positions 4, 44, 45, 72, 265, 266, 391, 393 and 394 of SEQ ID NO: 4, wherein the variant has cellobiohydrolase activity, wherein the variant has increased specific performance relative to a cellobiohydrolase without the substitution at one or more positions corresponding to positions 4, 44, 45, 72, 265, 266, 391, 393 and 394 of SEQ ID NO: 4, and wherein the variant has at least 90% sequence identity, but less than 100% sequence identity, to the mature polypeptide of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, or SEQ ID NO: 52.
US Pat. No. 10,557,128

PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING

Purdue Research Foundatio...

1. A conjugate, or a pharmaceutically acceptable salt thereof, comprising a ligand of PSMA (B), a linker (L), and a drug (D), wherein the ligand includes one or more of a carbon-sulfur double bond, a phosphorus-sulfur double bond, a phosphorus-sulfur single bond, a thioester, or a combination thereof, and wherein the linker is covalently bound to the drug and the linker is covalently bound to the ligand, and wherein the linker comprises a chain of at least seven atoms, and wherein the linker does not include a releasable linker.
US Pat. No. 10,557,130

ARGININE DEIMINASE MUTANT AND METHODS OF USING THE SAME

Jiangnan University, Jia...

1. An arginine deiminase mutant, comprising the amino acid sequence set forth in SEQ ID NO: 1, wherein the mutant comprises mutation Gly292Pro compared to a parent arginine deiminase, greater enzyme activity and greater temperature stability than the parent arginine deiminase.
US Pat. No. 10,556,876

PROCESS FOR THE PREPARATION OF GAMMA VALEROLACTONE FROM LEVULINIC ACID

DSM IP ASSETS B.V., Heer...

1. A process for preparing gamma valerolactone (GVL) from levulinic acid (LA), said process comprising the steps of:a) subjecting LA to a hydrogenation reaction at a temperature between 100 and 180° C. in the presence of hydrogen and a solid catalyst system comprising a metal and a support in the liquid phase to yield a first reaction mixture comprising GVL, hydroxypentanoic acid (4HPA), and water;
b) removing water from said first reaction mixture by subjecting the first reaction mixture to distillation or stripping to obtain a dewatered mixture; and
c) subjecting the dewatered mixture obtained in step b) to a further reaction at a temperature of 90 to 130° C. and in the presence of an acidic, homogeneous or heterogeneous catalyst to convert the 4-HPA in the dewatered mixture to GVL to thereby obtain a further reaction mixture.
US Pat. No. 10,557,133

METHODS AND COMPOSITIONS FOR NUCLEIC ACID SEQUENCING

ILLUMINA, INC., San Dieg...

1. A method for preparing a library of template nucleic acids to obtain sequence information from a target nucleic acid, said method comprising:(a) contacting a template nucleic acid with a plurality of transposomes to generate a tagmented template nucleic acid, wherein at least some of the transposomes each comprise a first transposon sequence, a second transposon sequence noncontiguous with said first transposon sequence, and a transposase associated with the first transposon sequence and the second transposon sequence, wherein a plurality of transposons are inserted into the target nucleic acid;
(b) compartmentalizing the tagmented template nucleic acid comprising said plurality of inserted transposons into each vessel of a plurality of vessels, wherein the compartmentalizing comprises distributing the tagmented template nucleic acid between the plurality of vessels to provide each vessel with an amount of tagmented template nucleic acid less than about one haploid equivalent of the target nucleic acid; and
(c) removing the transposase from the template nucleic acid.
US Pat. No. 10,557,135

SEQUENCE TAGS

Roche Sequencing Solution...

1. A mixture comprising a plurality of oligonucleotides, each of said plurality of oligonucleotides comprising a degenerated sequence segment, wherein said plurality of oligonucleotides:a. comprises at least 105 individual molecules;
b. does not comprise a representative with a homopolymer stretch longer than 3 nucleotide residues in the degenerated sequence segment,wherein said degenerated sequence segment comprises one subsegment or more than one identical subsegments, wherein the subsegment has a sequence X1-X2-X3-X4, wherein X1 is a degenerated base region comprising a first set of three different bases or base analogs, X2 is a degenerated base region comprising a second set of three different bases or base analogs, X3 is a degenerated base region comprising a third set of three different bases or base analogs, and X4 is a degenerated base region comprising a fourth set of three different bases or base analogs, wherein said first, second, third and fourth sets are different from each other.
US Pat. No. 10,556,880

NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES

R.J. Reynolds Tobacco Com...

1. Asalt of nicotine and 3,5-dihydroxybenzoic acid, wherein the salt is in an anhydrous form characterized by an X-ray powder diffraction pattern having peaks at one or more of the following 2-theta diffraction angles: 12.7, 17.8, 19.7, 20.2, 21.3, 24.5, 24.9, 25.8, and 29.8.
US Pat. No. 10,557,136

IN VIVO DELIVERY OF OLIGONUCLEOTIDES

Oncolmmunin Inc., Gaithe...

1. A method for modulating a target nucleic acid or protein in a subject, said method comprising administering to the subject an effective amount of an H-type excitonic structure (HES)-oligonucleotide containing a therapeutic oligonucleotide that specifically hybridizes to a target nucleic acid sequence in vivo and thereby modulates the level of a protein encoded or regulated by the nucleic acid.
US Pat. No. 10,556,882

CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR

Aragon Pharmaceuticals, I...

1. A crystalline Form H of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide that exhibits an an X-ray powder diffraction (XRPD) pattern with characteristic peaks at 8.0±0.1°2-Theta, 14.7±0.1°2-Theta, 15.9±0.1°2-Theta, 18.2±0.1°2-Theta, 25.7±0.1°2-Theta, and 26.7±0.1°2-Theta.
US Pat. No. 10,557,138

COMPOSITIONS AND METHODS FOR VIRUS CONTROL IN VARROA MITE AND BEES

BEEOLOGICS, INC., St. Lo...

1. A method of reducing viral load or suppressing viral replication in a Varroa destructor mite infected by a virus, the method comprising providing to the Varroa destructor mite infected by a virus a composition comprising an effective amount of at least one double-stranded RNA (dsRNA) which comprises a nucleic acid sequence that is identical or complementary to a sequence of at least 21 contiguous nucleotides of a viral gene in said virus, wherein the dsRNA downregulates expression of said viral gene in the Varroa destructor mite, thereby reducing viral load or suppressing viral replication in the Varroa destructor mite.
US Pat. No. 10,557,139

ANGIOPOIETIN-LIKE 3 (ANGPTL3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

Alnylam Pharmaceuticals, ...

1. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of Angiopoietin-like 3 (ANGPTL3), comprising a sense strand and an antisense strand,wherein the antisense strand comprises at least 17 contiguous nucleotides which differ by no more than three nucleotides from the nucleotide sequence of 5?-AAAGACUGAUCAAAUAUGUUGAG-3? (nucleotides 274-296 of SEQ ID NO:1),
wherein each strand is independently 17-25 nucleotides in length,
wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides,
wherein at least one of the modified nucleotides is selected from the group consisting of a 2?-O-methyl modified nucleotide, a 2?-fluoro modified nucleotide, a nucleotide comprising a 5?-phosphorothioate group, and a 2?-amino modified nucleotide, and
wherein a ligand comprising an N-acetylgalactosamine (GalNAc) derivative is conjugated to at least one strand of the dsRNA agent.
US Pat. No. 10,557,140

CTLA-4-TARGETING TRANS-SPLICING RIBOZYME FOR DELIVERY OF CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF

INDUSTRY-ACADEMIC COOPERA...

1. A recombinant vector, comprising a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)-targeting trans-splicing ribozyme expression cassette for delivery of a chimeric antigen receptor, wherein the expression cassette includes: (i) a CTLA-4-targeting trans-splicing ribozyme; and (ii) a polynucleotide encoding a chimeric antigen receptor connected to 3? exon of the ribozyme.
US Pat. No. 10,557,141

PLANT TRANSFORMATION METHOD

BASF PLANT SCIENCE COMPAN...

1. A method for producing a transgenic plant, comprising the steps of:a) providing a wounded transformable explant, comprising a hypocotyl or a portion thereof, at least one cotyledon, and wounded tissue selected from a group consisting of:
i. wounded meristematic tissue of a primary or higher leaf node,
ii. wounded meristematic tissue of the cotyledonary node; and
iii. wounded epicotyl tissue;
b) transforming cells of said wounded tissue with a polynucleotide comprising at least one plant expression cassette comprising a selectable marker gene;
c) transferring said explant with transformed cells from step b) to a growing medium by inserting the hypocotyl, or portion thereof, of said explant with transformed cells from step b) into said growing medium comprising at least one selection compound for said selectable marker gene, wherein the explant is placed in an upward position in the growing medium;
d) allowing said explant from step c) to form a shoot and/or allowing the shoot to elongate, wherein said shoot comprises plant cells comprising said polynucleotide comprising said least one plant expression cassette comprising said selectable marker gene; and
e) producing the transgenic plant by either (1) regenerating the transgenic plant from said shoot without separating the shoot or (2) separating the shoot and then regenerating the transgenic plant from the separated shoot,
wherein, in steps c) and d), the transformed plant cells of the explant are not in direct contact with the surface of the growing medium comprising the selection compound, and
wherein the hypocotyl, or portion thereof, is not transformed with the polynucleotide comprising the at least one plant expression cassette.
US Pat. No. 10,557,142

PLANT REGULATORY ELEMENTS AND USES THEREOF

Monsanto Technology LLC, ...

1. A recombinant DNA molecule comprising a polynucleotide selected from the group consisting of:a) a polynucleotide with at least 95 percent sequence identity to SEQ ID NO: 11, wherein the polynucleotide has promoter activity;
b) a polynucleotide comprising SEQ ID NO: 11; and
c) a fragment comprising at least 150 contiguous nucleotides of SEQ ID NO: 11, wherein the fragment has promoter activity;
wherein said DNA molecule is operably linked to a heterologous transcribable DNA molecule.
US Pat. No. 10,557,143

TRANSGENIC PLANTS HAVING INCREASED TOLERANCE TO ALUMINUM

Ceres, Inc., Thousand Oa...

1. A transgenic plant or progeny thereof comprising a nucleic acid, said nucleic acid comprising a regulatory region operably linked to a polynucleotide, wherein the polynucleotide has 95 percent or greater sequence identity to the nucleotide sequence set forth in SEQ ID NO: 1 or wherein the polynucleotide encodes a polypeptide having 95 percent or greater sequence identity to the amino acid sequence set forth in SEQ ID NO:2, wherein the regulatory region is heterologous with respect to the polynucleotide, and wherein the transgenic plant has been selected for increased yield when grown in soil comprising elevated levels of Al3+ as compared to the corresponding yield of a control plant that does not comprise said nucleic acid.
US Pat. No. 10,557,144

EXPRESSION OF THERMOSTABLE STARCH SYNTHASE GENES IMPROVES THE YIELD IN HEAT STRESS

Kansas State University R...

1. A genetically-modified plant having increased tolerance to heat stress as compared to a control plant, wherein said genetically-modified plant comprises a heterologous exogenous nucleic acid encoding soluble starch synthase from grape or cottonwood, wherein said soluble starch synthase from grape or cottonwood is expressed in said genetically-modified plant, said exogenous nucleic acid comprising a nucleotide sequence of SEQ ID NO:3 or 5, or a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 4 or 6.
US Pat. No. 10,557,145

FLAGELLIN-SENSING 3 (‘FLS3’) PROTEIN AND METHODS OF USE

BOYCE THOMPSON INSTITUTE ...

1. A nucleic acid construct comprising:a nucleic acid molecule that encodes a FLAGELLIN-SENSING 3 (“FLS3”) protein, wherein said nucleic acid molecule encodes a polypeptide having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO: 5;
a 5? heterologous DNA promoter sequence; and
a 3? terminator sequence, wherein the nucleic acid molecule, the DNA promoter sequence, and the terminator sequence are operatively coupled to permit transcription of the nucleic acid molecule.
US Pat. No. 10,557,148

COMPOSITIONS AND METHODS FOR DETERRING FEEDING BY PSYLLIDS

Cornell University, Itha...

1. A plant comprising at least a single transgene encoding a heterologous polypeptide conferring on said plant expressing said polypeptide resistance to a hemipteroid sap-sucking insect;wherein said transgene comprises a lectin gene having at least 95% identity to SEQ ID NO:5; and wherein said heterologous polypeptide has at least 95% identity to SEQ ID NO:6.
US Pat. No. 10,556,893

CYTOCHROME P450 INHIBITORS AND USES THEREOF

ANGION BIOMEDICA CORP., ...

1. A compound selected from the group consisting of: 4-(6-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)benzo[d]thiazol-2-yl)benzoic acid; 4-(6-(2-ethyl-1-(4H-1,2,4-triazol-4-yl)butyl)benzo[d]thiazol-2-yl)benzoic acid; 2-chloro-4-(6-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)benzo[d]thiazol-2-yl)benzoic acid, 2-chloro-4-(6-(2-ethyl-1-(4H-1,2,4-triazol-4-yl)butyl)benzo[d]thiazol-2-yl)benzoic acid, 4-(6-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)benzo[d]thiazol-2-yl)-2-(trifluoromethyl)benzoic acid, 4-(6-(2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl)benzo[d]thiazol-2-yl)-2-fluorobenzoic acid, 4-(6-(2-ethyl-1-(4H-1,2,4-triazol-4-yl)butyl)benzo[d]thiazol-2-yl)-2-(trifluoromethyl)benzoic acid, and 4-(6-(2-ethyl-1-(4H-1,2,4-triazol-4-yl)butyl)benzo[d]thiazol-2-yl)-2-fluorobenzoic acid.
US Pat. No. 10,559,456

SYSTEMS AND METHODS FOR ANALYZING AN EXTRACTED SAMPLE USING AN IMMISCIBLE EXTRACTION SOLVENT

Purdue Research Foundatio...

1. A method for analyzing an analyte in a sample, the method comprising:introducing a solvent into a hollow body comprising a distal tip;
introducing a sample into the hollow body, wherein the solvent does not mix with the sample;
extracting at least one analyte from the sample into the solvent in the hollow body;
applying a voltage to the solvent comprising the extracted analyte in the hollow body so that the analyte is expelled from the distal tip of the body, thereby generating ions of the analyte which are transferred to a mass spectrometer; and
analyzing in the mass spectrometer the ions that have been expelled from the hollow body and that enter the mass spectrometer.
US Pat. No. 10,557,152

YEAST HOST CELLS AND METHODS FOR PRODUCING FATTY ALCOHOLS

The Regents of the Univer...

1. A genetically modified yeast cell comprising the following modifications: (a) an increased expression of Mus musculus fatty acid reductase (FAR) (MmFAR1); (b) an increased expression of acetyl-CoA carboxylase (ACC1); (c) an increased expression of fatty acid synthase 1 (FAS1);(d) an increased expression of fatty acid synthase 2 (FAS2); (e) a reduced expression of or deleted for diacylglycerol O-acyltransferase (DGA1); (f) a reduced expression of or deleted for homolog of fatty acid aldehyde (HFD1); (g) a reduced expression of or deleted for alcohol dehydrogenase (ADH6); (h) an increased expression of a Saccharomyces cerevisiae ACC1 comprising the mutations S659A and S1157A; (i) a reduced expression of or deleted for glutamate dehydrogenase (GDH1); and (j) an increased expression of a delta(9) fatty acid desaturase encoded by OLE1; wherein the genetically modified yeast cell is capable of producing at least 1.0 g of fatty alcohol per liter of medium.
US Pat. No. 10,557,153

DEGRADATION OF LIGNOCELLULOSIC MATERIAL

DSM IP ASSETS B.V., Heer...

1. A method for the treatment of corn stover which method comprises contacting pretreated corn stover with a composition comprising three or more enzyme activities, said enzyme activities being cellulase and/or hemicellulase activities, wherein:a) the composition comprises an endoglucanase, cellobiohydrolase and ?-glucosidase which are derived from Talaromyces emersonii and the composition is provided in an amount from 0.15 to 1.5 mg enzyme protein per gram corn stover dry matter (mg EP/g CS dm)
b) the pH during the treatment is about 4.5 or lower,
c) the pretreated corn stover is produced by a method comprising exposing corn stover to an acid prior to contacting the corn stover with the composition,
d) the treatment is carried out at a dry matter content of 15% to 25%; and
e) said method results in at least 80% conversion of cellulose to a sugar or sugars.
US Pat. No. 10,557,155

METHODS AND SYSTEMS FOR BIOLOGICAL COAL-TO-BIOFUELS AND BIOPRODUCTS

The University of Wyoming...

1. A method for producing biofuel from coal comprising the steps of:pretreating coal first with an alkali comprising NaOH and second with an acid comprising H2SO4 to provide solubilized coal;
removing water insoluble fractions from said solubilized coal;
bioreacting said solubilized coal with at least one type of coal-utilizing bacteria;
generating biomass and lipids from said step of bioreacting said solubilized coal with at least one type of coal-utilizing bacteria;
converting said lipids into biodiesel with a transesterification reaction in a biodiesel production unit;
producing biodiesel and glycerol from said transesterification reaction;
collecting said biodiesel and glycerol;
anaerobically digesting excess biomass that cannot be converted into biodiesel;
producing methane from said step of anaerobically digesting said excess biomass; and
adding at least some of said glycerol to said step of anaerobically digesting said excess biomass.
US Pat. No. 10,557,156

BACTERIUM CONSTITUTIVELY PRODUCING MONOPHOSPHORYL LIPID A AND METHOD OF PRODUCING MONOPHOSPHORYL LIPID A BY USING BACTERIUM

KOREA INSTITUTE OF SCIENC...

1. A recombinant bacterium that constitutively produces monophosphoryl lipid A (MLA) not conjugated to 2-keto-3-deoxy-D-manno-octulosonate (Kdo) moiety, wherein the recombinant bacterium comprises(a) (i) a genetic modification that increases the copy number of a gene encoding Lipid A 1-phosphatase (LpxE) polypeptide, (ii) at least one exogenous polynucleotide encoding a LpxE polypeptide, or (iii) a genetic modification wherein the endogenous promoter of an endogenous polynucleotide encoding a LpxE polypeptide is replaced with a heterologous promoter,
(b) a chromosomal mutation that is a disruption in an endogenous polynucleotide that encodes an undecaprenyl pyrophosphate phosphatase (Und-PP phosphatase), and a chromosomal mutation that is a disruption in an endogenous polynucleotide that encodes a phosphatidylglycerophosphate phosphatase (PGP phosphatase), and
(c) a mutation that is a disruption in an endogenous polynucleotide that encodes a 3-deoxy-D-manno-octulosonic acid transferase (KdtA) polypeptide.
US Pat. No. 10,557,157

PROCESS FOR ENZYMATIC HYDROLYSIS OF LIGNOCELLULOSIC MATERIAL AND FERMENTATION OF SUGARS

DSM IP ASSETS B.V., Heer...

1. A process for preparation of a fermentation product from lignocellulosic material, comprising:enzymatic hydrolysis of the lignocellulosic material using an enzyme composition comprising at least two cellulases to obtain a sugar product, wherein the enzymatic hydrolysis comprises at least:
a) a first stage wherein the enzymatic hydrolysis is performed at a first temperature, in one or more first container,
b) a second stage wherein the enzymatic hydrolysis is performed at a second temperature, in one or more second container, wherein the second temperature is lower than the first temperature and wherein oxygen is added to the hydrolysis during at least part of the second stage, wherein the oxygen concentration (DO) in the lignocellulosic material present during the enzymatic hydrolysis of said second stage is at least 0.0023 mol/m3 when measured at atmospheric pressure and about 32° C., and
c) a fermentation, wherein said sugar product obtained is fermented to said fermentation product, in one or more third container, and optionally recovering the fermentation product.
US Pat. No. 10,556,133

COMPOSITION AND METHOD FOR STRENGTHENING HAIR FIBER

Momentive Performance Mat...

1. A hair fiber strengthening composition which comprises an aqueous vehicle and a hair strengthening agent which is at least one metal compound of the general formula:Me+(X?)n wherein Me+ is the cation of a metal having a valence equal to subscript n, subscript n is 2 or 3 and each X? independently is an anion of (i) an oxidized carbohydrate of the formula:?O—C(O)—Rwherein R is the residue of the same or different carbohydrate, or an anion (ii) derived from the same or different inorganic or organic acid, provided, there is at least one anion (i), wherein the mole ratio of ?O—C(O)—R anions to Me cations is from above about 1.0 to about 2.0, and wherein the composition having a pH of from about 6 to about 11.
US Pat. No. 10,557,158

PROCESSES AND SYSTEMS FOR PREPARATION OF NUCLEIC ACID SEQUENCING LIBRARIES AND LIBRARIES PREPARED USING SAME

10X GENOMICS, INC., Plea...

1. A method for nucleic acid processing, comprising:(a) synthesizing a double-stranded nucleic acid molecule comprising at least one uracil;
(b) at one or more sites corresponding to said at least one uracil, generating a plurality of single-stranded nucleic acid molecules from said double-stranded nucleic acid molecule; and
(c) using a nucleic acid barcode molecule comprising a barcode sequence to generate a barcoded nucleic acid molecule comprising (i) a sequence of a single-stranded nucleic acid molecule of said plurality of single-stranded nucleic acid molecules or reverse complement thereof; and (ii) said barcode sequence or reverse complement thereof.
US Pat. No. 10,555,877

LIGHT-CURING DENTAL COMPOSITES WITH INCREASING OPACITY

Ivoclar Vivadent AG, Sch...

1. Radically polymerizable dental material which comprises(a) 5 to 40 wt.-% of at least one polyfunctional radically polymerizable monomer,
(b) 2 to 15 wt.-% of at least one monofunctional radically polymerizable monomer,
(c) 0.1 to 3.0 wt.-% of at least one photoinitiator for the radical polymerization and 10 to 85 wt.-% of at least one filler,characterized in that the dental material comprises at least one filler (d) and that the mixture of the monomers (a) and (b) has a refractive index of from 1.50 to 1.70 and in that the refractive index of the monomer mixture before the curing corresponds to the refractive index of the filler used or is higher by up to 0.013 and after the curing is higher than the refractive index of the filler (d) by at least 0.02, and in that the dental material in addition to the filler (d) comprises, relative to the total quantity of filler,0 to 15 wt.-% of at least one filler (e) having a refractive index which is lower than the refractive index of the mixture of the monomers (a) and (b) by 0.02 to maximally 0.155,
0 to 10 wt.-% of at least one filler which does not scatter visible light and does not influence the translucence, and
maximally 15.5 wt.-% of filler (f) which does not fall within any of the filler categories.
US Pat. No. 10,557,159

METHOD OF CONVERTING RB TO RD BY USING CUTINASE UNDER STEPWISE CHANGING TEMPERATURES

Jiangnan University, Wux...

1. A method for producing Rebaudioside D (RD) from Rebaudioside B (RB), wherein said method uses a cutinase to catalyze the esterification of RB and sophorose to produce RD under temperatures which are reduced stepwise.
US Pat. No. 10,557,160

TRANSGENIC BACTERIA WITH EXPANDED AMINO ACID USAGE AND NUCLEIC ACID MOLECULES FOR USE IN THE SAME

BOARD OF REGENTS, THE UNI...

1. A recombinant nucleic acid molecule, wherein the molecule encodes a tRNA and is at least 90% identical to SEQ ID NO: 18, and comprising one or more of the following features:(i) a G or C at a position corresponding to position 7;
(ii) a T at a position corresponding to position 49;
(iii) a A or C at a position corresponding to position 50;
(iv) a T at a position corresponding to position 64;
(v) a G or A at a position corresponding to position 65; and/or
(vi) a G, T or C at a position corresponding to position 66.
US Pat. No. 10,555,879

POLYUREA CAPSULE COMPOSITIONS

1. A microcapsule composition comprising a first microcapsule and a second microcapsule, whereinthe first microcapsule has a zeta potential of 10 mV or greater,
the second microcapsule has a zeta potential of 5 mV or less,
the weight ratio of the first microcapsule and the second microcapsule is between 1:10 and 10:1,
the first microcapsule has a first oil core and a first microcapsule wall encapsulating the first oil core,
the first oil core contains a first active material at a level of 5% to 95% by weight of the first microcapsule,
the second microcapsule contains a second oil core and a second microcapsule wall encapsulating the second oil core, and
the second oil core contains a second active material at a level of 5% to 95% by weight of the second microcapsule; and
wherein the second microcapsule wall is formed from an encapsulating polymer that is not starch.
US Pat. No. 10,557,161

RECOMBINANT HUMAN ADA2 AND ADA2 FUSION PROTEINS AND METHODS FOR TREATING ADA2 DEFICIENCIES

Alexion Pharmaceuticals, ...

1. A pharmaceutical composition comprising an isolated human adenosine deaminase 2 (ADA2) protein, or biologically active fragment thereof, and a pharmaceutically acceptable carrier, wherein the ADA2 protein, or biologically active fragment thereof, increases differentiation of monocytes into M2 macrophages, and wherein the ADA2 protein, or biologically active fragment thereof, comprises SEQ ID NO:1, or a functional peptide having one or more asparagine-to-alanine substitutions at amino acid position 127, 174, 185, and/or 378 of SEQ ID NO:1.
US Pat. No. 10,555,880

SODIUM ZINC ALGINATE STRUCTURANT AND METHODS FOR MAKING AND USING THE SAME

Colgate-Palmolive Company...

1. A method of making a sodium zinc alginate structurant comprising:combining a sodium alginate, a zinc compound, and a liquid media; and
mixing the sodium alginate, the zinc compound, and the liquid media to make a sodium zinc alginate structurant,
wherein combining comprises combining the sodium alginate and the zinc compound in a weight ratio of about 0.04:1,
wherein the zinc compound comprises zinc oxide and zinc citrate in a weight ratio of about 2:1, and
wherein the sodium zinc alginate structurant has a viscosity of about 1,200 cP to about 2,000 cP at 25° C.
US Pat. No. 10,556,906

QUINAZOLINE COMPOUND

ASTELLAS PHARMA INC., To...

1. A compound or the salt thereof,wherein the compound is selected from the group consisting of
(+)-1-(7-{8-ethoxy-7-(5-methyl-1H-indazol-4-yl)-2-[(1-methylpiperidin-4-yl)oxy]-6-vinylquinazolin-4-yl}-2,7-diazaspiro[3.5]non-2-yl)prop-2-en-1-one,
(+)-1-{7-[6-cyclopropyl-2-{[1-(2-methoxyethyl)piperidin-4-yl]oxy}-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one,
(+)-1-{7-[2-{[1-(2-methoxyethyl)piperidin-4-yl]oxy}-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)-6-vinylquinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one,
(+)-1-{7-[2-{[1-(2-ethoxyethyl)piperidin-4-yl]oxy}-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)-6-vinylquinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one,
(+)-1-{7-[6-cyclopropyl-2-{[1-(3-methoxypropyl)piperidin-4-yl]oxy}-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one,
(+)-1-{7-[7-(5-methyl-1H-indazol-4-yl)-2-{[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]oxy}-8-(2,2,2-trifluoroethoxy)-6-vinylquinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one, and
(+)-1-{7-[2-{[1-(2-hydroxy-2-methylpropyl)piperidin-4-yl]oxy}-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)-6-vinylquinazolin-4-yl]-2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one.
US Pat. No. 10,557,162

IDENTIFICATION OF MICROORGANISMS USING MALDI-TOF-MS ON-PLATE EXTRACTION

BECTON, DICKINSON AND COM...

1. A method for characterizing at least one microorganism in a sample for identification of microorganisms therein, the method comprising:(a) obtaining a sample containing at least one microorganism as a microbial suspension in a solution selected from the group consisting of water and an organic solvent;
(b) depositing at least a portion of the microbial suspension on a solid surface adapted to be placed in an apparatus configured to determine the identity of microorganisms by mass spectrometry;
(c) drying the sample;
(d) treating the sample with an organic solvent;
(e) drying the sample;
(f) treating the sample with a solution selected from the group consisting of formic acid in water and formic acid in an organic solvent, wherein the formic acid is at a volume percent of at least 70% when combined with the sample;
(g) drying the sample;
(h) placing a matrix over the treated sample;
(i) drying the sample; and
(j) identifying the at least one microorganism by a mass spectrometry.
US Pat. No. 10,555,881

STABILIZATION OF NONIONIC POLYSACCHARIDES WITH BUTYLENE GLYCOL

1. A composition comprising an emulsion of an aqueous phase in a lipophilic phase, wherein the composition comprises 30-60 wt % water, 10-30 wt % butylene glycol, sclerotium gum, 1-10 wt % glycerol and one or more lipophilic materials, wherein the lipophilic phase constitutes 25-50 wt % of the composition, and wherein the one or more lipophilic materials comprise one or more emollients selected from the group consisting of isopropyl myristate, caprylic/capric triglyceride, octyldodecanol, caprylyl glycol, dimethicone, bis-PEG/PPG-14/14 dimethicone, PEG-9 polydimethylsiloxyethyl dimethicone, vinyl dimethicone/methicone silsesquioxane crosspolymer, and combinations thereof.
US Pat. No. 10,555,882

MONOUNSATURATED FATTY ACID FOR NAILCARE

1. A cosmetic nailcare method for treating brittle, fragile, soft or split nails, or nails which have a dull appearance, the method comprising:administering, via the oral route, coriander seed oil as an active agent to an individual in need thereof,
wherein the coriander seed oil contains petroselinic acid, the content of which is such that the daily dose of petroselinic acid ranges from 80 to 1000 mg/d.
US Pat. No. 10,557,164

METHODS AND COMPOSITIONS FOR THE ANALYSIS OF BIOLOGICAL MOLECULES

Sequenom, Inc., San Dieg...

1. A method for analyzing a target nucleic acid in a sample, which comprises:(a) hybridizing a plurality of nucleic acid probes to the target nucleic acid, wherein each probe comprises a target binding region having a polynucleotide sequence complementary to the target nucleic acid and a non-target binding detector region having a polynucleotide sequence not complementary to the target nucleic acid wherein such polynucleotide sequence provides information about the chromosomal location of the target, wherein:
i) the plurality of nucleic acid probes comprise probe pairs,
ii) the end of the complementary nucleotide sequence of one probe is adjacent to the end of the other probe in the same probe pair when hybridized to the target nucleic acid,
iii) each detector region is located on the end of the probe opposite the complementary nucleotide sequence,
iv) the end of the detector region of a first probe of a probe pair is in proximity to the end of the detector region of a second probe of a different probe pair, with the proviso that the end of a detector region of one probe in two probe pairs is not in proximity to the end of the detector region of another probe; and
v) the first probe flanks the second probe when the first probe and second probe are hybridized to the target nucleic acid;
(b) joining the ends of the complementary nucleotide sequences of the probes in the same probe pair when hybridized to the target nucleic acid,
by ligation, if there are no bases there between the ends of the complementary nucleotide sequences of the probes in the same probe pair, or
by extension followed by ligation, if there are one or more bases there between the ends of the complementary nucleotide sequences of the probes in the same probe pair,
(c) joining the ends of detector regions in proximity to one another, thereby forming a linked probe molecule; and
(d) determining the sequence of the linked probe molecule, whereby the target nucleic acid is analyzed.
US Pat. No. 10,556,140

AZEOTROPE-LIKE COMPOSITIONS OF CIS-1,1,1,4,4,4-HEXAFLUORO-2-BUTENE

Honeywell International I...

1. An azeotrope-like composition comprising from greater than 59.4 wt % to 97.1 wt % of the compound cis-1,1,1,4,4,4-hexafluoro-2-butene (Z-HFO-1336mzzm) and from 2.9 wt % to less than 40.6 wt % of water.
US Pat. No. 10,556,909

SYNTHETIC PROCESS AND INTERMEDIATES

Avista Pharma Solutions, ...

1. A compound 1-(6-bromospiro[1H-isobenzofuran-3,3?azetidine]-1?-yl)-3,3,3-trifluoro-propane-1-one.
US Pat. No. 10,555,885

LOW VISCOUS COSMETIC COMPOSITION USING A NATURAL EMULSIFYING AGENT

AMOREPACIFIC CORPORATION,...

1. A method for enhancing luster of skin and whitening skin of a subject, comprising applying to the skin of the subject a cosmetic composition containing:a mixture of a first naturally-derived saccharide-based surfactant selected from the group consisting of polyglyceryl-3-methyl glucose distearate, inulin lauryl carbamate, and a mixture thereof; and a second naturally-derived saccharide-based surfactant selected from the group consisting of sucrose fatty acid ester, cetearyl glucoside, arachidyl glucoside, C12-20 alkylglucoside, and a mixture thereof;
a naturally-derived oil-soluble ingredient; and
a mixture of niacinamide and at least one ingredient selected from the group consisting of green tea polysaccharide and mushroom-derived yeast extract; and
wherein a weight ratio of the first naturally-derived saccharide-based surfactant to the second naturally-derived saccharide-based surfactant is 0.4 to 2.5;
wherein the composition has a viscosity of 1,000 cps to 4,000 cps as measured with Spindle No. 3 at 12 rpm using a Brookfield viscometer;
wherein the composition contains a mixture of the first naturally-derived saccharide-based surfactant and the second naturally-derived saccharide-based surfactant in an amount of 0.20 wt. % to 1.50 wt. % with respect to the total weight of the composition;
wherein the composition contains the naturally-derived oil-soluble ingredient in an amount of 5 wt. % to 15 wt. % with respect to the total weight of the composition;
wherein the content of the at least one ingredient selected from green tea polysaccharide and mushroom-derived yeast extract is 0.01 wt. % to 5.0 wt. % with respect to the total weight of the composition; and
wherein the content of the niacinamide is 2 wt. % with respect to the total weight of the composition.
US Pat. No. 10,555,886

COMPOSITION OF ALGAL EXTRACTS FOR PREVENTING AND TREATING PERIODONTAL DISEASE

FAR EAST BIO-TEC CO., LTD...

1. A method for inhibiting growth of Porphyromonas gingivalis in a subject, the method comprising administering to said subject an effective concentration of a C-phycocyanin in an extract solution,wherein the effective concentration is greater than 50 ?g/ml in the C-phycocyanin extract solution.
US Pat. No. 10,557,168

SENSING APPARATUS FOR AMPLIFICATION AND SEQUENCING OF TEMPLATE POLYNUCLEOTIDES AND ARRAY FOR AMPLIFICATION OF TEMPLATE POLYNUCLEOTIDES

DNAE Group Holdings Limit...

1. An array for amplification and sequencing of template polynucleotides, the array comprising:a plurality of wells wherein each well is exposed to an ISFET;
a plurality of capture beads, wherein each capture bead comprises a single template binding site, wherein the wells and capture beads are relatively sized so that only one bead will fit into each well;
a removable seal arranged to cover the wells and isolate each well from adjacent wells; and
a heating element.
US Pat. No. 10,555,888

NAIL COMPOSITIONS CONTAINING LATEX AND SULFOPOLYESTER COMPOUND

1. A nail composition comprising water, at least one plasticizer, at least one high molecular weight latex comprising at least one styrene group, at least one latex lacking styrene groups, and at least one low molecular weight sulfopolyester compound, wherein the sulfopolyester compound is polyester-5, and wherein the composition is physiologically acceptable.
US Pat. No. 10,557,170

THROMBOEMBOLIC DISEASE MARKERS

Gendiag.exe, S.L., Barce...

1. A method comprising:a) determining in a sample isolated from a human subject the presence or absence of each of the following polymorphisms:
Serpin A10 (protein Z inhibitor) Arg67Stop (rs2232698),
Serpin CI (antithrombin) Ala384Ser (Cambridge II),
factor XIIC46T (rsl801020),
factor XIII Va134Leu (rs5985),
Factor II (prothrombin) G20210A (rsl799963),
factor V Leiden Arg506Gln (rs6025),
factor V Cambridge Arg306Thr,
factor V Hong Kong Arg306Gly,
ABO blood group rs8176719,
ABO blood group rs7853989,
ABO blood group rs8176743, and
ABO blood group rs8176750;
b) detecting the presence of at least one of said polymorphisms in said subject;
c) identifying the subject with at least one of said polymorphisms for treatment and
d) administering to the subject identified in step c) an anticoagulant and/or antithrombotic therapy.
US Pat. No. 10,555,889

COMPOSITIONS FOR SPORE REMOVAL

3M INNOVATIVE PROPERTIES ...

1. A composition comprising:a) at least 85 wt % of a hydroalcoholic solution, the hydroalcoholic solution comprising:
at least 1 wt % water based on the total weight of the hydroalcoholic solution; and
30 wt % to 85 wt % of at least one C1 to C4 alkyl alcohol based on the total weight of the hydroalcoholic solution; and
b) acrylate copolymer particles dispersed in the hydroalcoholic solution, the acrylate copolymer particles comprising the reaction product of a reaction mixture, the reaction mixture comprising monomers, the monomers comprising:
from 5 wt % to 50 wt % of at least one high Tg monomer having an alkyl carbon chain length in a range from 1 to 3, and having a Tg from 40° C. to 150° C., where the wt % of the high Tg monomer is with respect to the total weight of the monomers in the reaction mixture; and
from 20 wt % to 80 wt % of at least one low Tg monomer having an alkyl carbon chain length of at least 4 and having a Tg from ?20° C. to ?60° C. where the wt % of the low Tg monomer is with respect to the total weight of the monomers in the reaction mixture,
wherein the particles have a number average diameter of at least 100 nm and not greater than 500 nm.
US Pat. No. 10,556,915

POLYMORPHIC MIXTURE OF RIFAXIMIN AND ITS USE FOR THE PREPARATION OF SOLID FORMULATIONS

EUTICALS SPA, Milan (IT)...

1. A Rifaximin polymorphic mixture of ?/? form in a relative ratio of 85/15±3, characterized by an X-Ray spectrum with characteristic 2theta values at (relative intensity): 5.32 (11%), 5.78 (19%), 6.50 (27%), 7.24 (45%), 7.82 (61%), 8.80 (100%), 10.50 (59%), 11.02 (35%), 11.58 (32%), 13.08 (20%), 14.42 (26%), 17.32 (48%), 17.68 (93%), 18.58 (79%), 19.52 (61%), 21.04 (52%), 21.60 (30%), and 21.92 (46%).
US Pat. No. 10,557,171

METHODS FOR THE TREATMENT OF KIDNEY FIBROSIS

1. A method of treatment for kidney fibrosis and/or chronic kidney disease comprising; measuring a level of expression of SPARC related modular calcium binding 2 (Smoc2) in a test sample obtained from a subject; treating the subject with a kidney fibrosis treatment when the expression level is increased relative to a reference level, wherein the kidney fibrosis treatment is selected from the group consisting of: dialysis; transplant; low protein diet; an ACE inhibitor; an angiotensin H receptor blacker (ARB); lipid control; D-vitamin supplementation; phosphate control; anemia control; acidosis prevention; and uric acid control.
US Pat. No. 10,555,890

FLEXIBLE SOLID COSMETIC COMPOSITION COMPRISING ANIONIC SURFACTANTS AND SOLID PARTICLES, AND COSMETIC TREATMENT PROCESS

1. An aqueous cosmetic hair composition in flexible solid form, comprising:at least one anionic surfactant wherein at least one anionic surfactant is chosen from acyl isethionates represented by the following formula:
R—C(O)—O—CH2CH2SO3M
wherein:
R—C(O) is an acyl group comprising from 6 to 16 carbon atoms, and
M denotes a cosmetically acceptable counterion,
at least one type of solid full particles chosen from silicas, clays, pigments, pearlescent agents, or mixtures thereof, wherein the total amount of solid particles ranges from 6.7% to 15% by weight, relative to the total weight of the composition, and
water in an amount of 35% to 80% by weight;
wherein the total amount of anionic surfactant ranges from 25% to 70% by weight, relative to the total weight of the composition;
wherein the total amount of acyl isethionates ranges from 12% to 35% by weight, relative to the total weight of the composition, and
wherein the composition has a threshold stress at 25° C. of greater than or equal to about 100 Pa.
US Pat. No. 10,557,172

METHODS FOR SIMULTANEOUS AMPLIFICATION OF TARGET LOCI

Natera, Inc., San Carlos...

1. A method for amplifying and sequencing DNA, comprising:isolating cell-free DNA from a biological sample and tagging the isolated cell-free DNA, wherein each tagged DNA molecule comprises a molecular barcode;
performing a first PCR to simultaneously amplify at least 10 target loci using a universal primer and at least 10 target-specific primers in a single reaction volume;
performing a second, nested PCR to simultaneously amplify the at least 10 target loci using the universal primer and at least 10 inner target-specific primers in a single reaction volume;
performing high-throughput sequencing to sequence the amplified DNA comprising the target loci.
US Pat. No. 10,555,891

METHODS FOR TREATING CHEMICALLY TREATED HAIR

1. A method for treating chemically treated hair comprising:applying a hair-treatment composition to chemically treated hair within 30 minutes from when a chemical treatment composition is rinsed from the hair, the hair-treatment composition comprising:
one or more polyurethane latex polymers;
one or more silicone-organic polymer hybrid compounds;
one or more additional silicones that are different than the one or more silicone-organic polymer hybrid compounds; and
water; and
rinsing the hair-treatment composition from the hair within 30 minutes from applying the hair-treatment composition to the hair.
US Pat. No. 10,556,405

PRODUCTION METHOD FOR AEROGEL LAMINATE, AND AEROGEL LAMINATE ROLL

HITACHI CHEMICAL COMPANY,...

1. A production method for an aerogel laminate comprising a support, and an aerogel layer disposed on the support, the aerogel layer being a layer containing an aerogel having a structure derived from polysiloxane and having a thickness of 10 ?m to 200 ?m, the method comprising:a step of washing a wet gel laminate comprising the support and a wet gel layer disposed on the support by a roll-to-roll scheme.
US Pat. No. 10,556,917

METHOD FOR PREPARING BIS-(SILYLALKYL)CARBONATE ESTERS

UCHICAGO ARGONNE, LLC, C...

1. A method of preparing a bis-(silylalkyl)carbonate of Formula (I):(R1)(R2)(R3)Si—R4—O—C(?O)—O—R4—Si(R1)(R2)(R3); the method comprising the sequential steps of:
(a) contacting at least about two molar equivalents of silyl-substituted alcohol of Formula (II): (R1)(R2)(R3)Si—R4—OH with about 1 molar equivalent of an activated carbonyl compound of Formula (III): C(?O)Z2 in the presence of a catalyst in an aprotic solvent; and
(b) isolating the bis-(silylalkyl)carbonate of Formula (I) from the solvent;
wherein:
the catalyst comprises at least one material selected from the group consisting of a bicyclic amidine base, a bicyclic guanidine base, and a phosphazene base;
each of R1 and R2 independently is alkyl;
R3 is alkyl or —X1—Si(R5)(R6)(R7);
X1 is O or alkylene;
R4 is alkylene;
each of R5, R6, and R7 independently is alkyl; and
Z is 1-N-imidazolyl or 1-N-succinimidyl.
US Pat. No. 10,557,173

PROGNOSTIC METHODS, COMPOSITIONS AND KITS FOR PREDICTION OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) RELAPSE

MOR RESEARCH APPLICATIONS...

1. A method of treatment for acute lymphoblastic leukemia (ALL) in a mammalian subject, comprising:(a) contacting a test sample from the subject with nucleic acid molecules specific for miR-451, or miR-451 and miR-151-5p;
(b) determining the expression value of the miR-451, or miR-451 and miR-151-5p in the test sample;
(c) comparing the expression value of the miR-451, or miR-451 and miR-151-5p in the test sample with a control value of miR-451, or miR-451 and miR-151-5p; wherein lower expression of miR-451, or miR-451 and miR-151-5p in the test sample in comparison to the control indicates that the subject has an increased risk of ALL relapse; and
(d) if the subject does not have an increased risk of ALL relapse, administering to the subject a standard risk ALL treatment regimen selected from the group consisting of standard risk regimens of COG, ACS, BFM, and UKALL2003;
and if the subject has an increased risk of ALL relapse administering to the subject a high risk ALL treatment regimen selected from the group consisting of high risk regimens of COG, ACS, BFM, and UKALL2003.
US Pat. No. 10,555,892

FUNCTIONALIZED SILOXANE OR POLYSILOXANE COATED PARTICLES WITH ENHANCED LIGHT FILTERING PROPERTIES

Nanophase Technologies Co...

1. A coated powder comprising:(a) particles, and
(b) a coating, on the surface of the particles, comprising
optionally (1) silica moieties,
(2) organo oxysilane moieties selected from the group consisting of mono-organo oxysilane moieties, bi-organo oxysilane moieties and tri-organo oxysilane moieties, and
optionally (3) organo-substituted polysiloxane moieties
wherein the organo oxysilane moieties each have the formula R?nSiO4-n, with n=1, 2 or 3, each R? group is independently selected from the group consisting of alkyl, alkenyl, alkynyl, esters, amides and aromatic moieties having an absorption band maximum in the region of 280 nm to 780 nm, and
at least one organo oxysilane moiety comprises the aromatic moiety having an absorption band maximum in the region of 280 nm to 780 nm.
US Pat. No. 10,555,893

LEAVE-ON HAIR STYLING COMPOSITIONS AND METHODS OF USE

1. A leave-on hair styling composition comprising:(a) about 1 to about 50 wt. % of beeswax;
(b) about 0.1 to about 10 wt. % of one or more glucoside emulsifiers:
(c) about 0.1 to about 20 wt. % of two or more ester oils and/or emulsifying esters;
(d) about 20 to about 95 wt. % of water;
(e) about 0.1 to about 10 wt. % of one or more monomeric polyols; and
(f) about 0.1 to about 40 wt. % of one or more fatty acids and/or fatty alcohols,
wherein the composition is free of synthetic fatty acids containing from 6 to 48 carbon atoms.
US Pat. No. 10,555,894

PLANT EXTRACT COMPRISING SUCROSE ESTERS AS AN ACTIVE AGENT FOR USE IN COSMETIC, DERMATOLOGICAL OR NUTRICOSMETIC COMPOSITION

COSMO INTERNATIONAL INGRE...

1. A cosmetic, dermatological or nutracosmetic composition comprising:an effective amount of a plant extract from the calyx of one of the many plants of the Solanaceae family, of the Physalis genus, comprising mainly one or more moderately polar to non-polar sucrose esters having a carbon number of acyl groups from C1 to C10 for use as an active ingredient that is biologically active on skin, skin appendages and mucous membranes apart from any anti-inflammatory activity of the active ingredient, and
a physiological medium suitable for topical or oral administration,
wherein the composition is in the form of an oil-in-water or water-in-oil emulsion or multiple emulsions, or in the form of a a capsule, or tablet.
US Pat. No. 10,555,895

AQUEOUS EXTRACT OF PRUNUS PERSICA AND PROCESS FOR PREPARING THE SAME

ISP Investments LLC, Wil...

1. A process for obtaining an extract from Prunus persica L. comprising:(i) adding water to Prunus persica L. to make a mixture;
(ii) agitating said mixture for 2 hours and maintaining the temperature of the mixture from 25° C. to 70° C.;
(iii) filtering the mixture to remove solid Prunus persica L. am thus obtain the extract;
(iv) pasteurizing the extract overnight at a temperature below 70° C., wherein said extract of step (iv) is further clarified by sequential filtration from about 50 pm to about 20 pm porosity until about 0.5 pm to about 0.2 pm to yield the extract from Prunus persica, and wherein said Prunus persica extract of step (iv) is then diluted in a solvent selected from the group consisting of water, glycerol, ethanol, propanediol, butylene glycol, dipropylene glycol, ethoxylated or propoxylated glycols, cyclic polyols and mixtures thereof.
US Pat. No. 10,557,177

METHODS FOR ASSESSING TOXICITY

NANJING UNIVERSITY, Nanj...

2. A method for detecting water toxicity, comprising:ligating a CHOP promoter and a secreted embryonic alkaline phosphatase (SEAP) gene in a lentiviral plasmid to construct a lentiviral CHOP-SEAP plasmid vector;
transfecting the lentiviral CHOP-SEAP plasmid vector into Hela cells to construct a reporter gene cell line comprising transfected Hela cells;
concentrating 5 L water samples by solid phase extraction and then diluting with 2% DMSO to 1 mL to obtain concentrated water samples; diluting the concentrated water samples to four dilutions respectively comprising by volume 0, 0.02%, 1%, and 2% of the concentrated water samples;
performing parallel comparison tests and exposing the transfected Hela cells to the four dilutions for 24 hours to obtain treated Hela cells;
incubating culture supernatants of the treated Hela cells at 65° C. for 30 minutes; anddetecting a SEAP activity of the culture supernatants of the treated Hela cells by a SEAP Reporter Gene Assay kit;wherein:
detecting the SEAP activity comprises diluting the cell-based alkaline phosphatase standard to obtain standard dilutions; adding the standard dilutions and the culture supernatants of the treated Hela cells to a 96-well white plate and adding the SEAP substrate to each well; and incubating the 96-well white plate at room temperature for 10-30 minutes and detecting the chemiluminescence of the standard dilutions and the culture supernatants of the treated Hela cells.
US Pat. No. 10,555,896

SKIN PENETRATION ENHANCING METHOD AND ITS PENETRATION ENHANCER

XIAMEN UNIVERSITY, Xiame...

1. A skin penetration enhancer, wherein:the enhancer comprises sponge spicules or a composition containing sponge spicules,
the sponge spicules are derived from sponge Haliclona sp,
the composition containing sponge spicules is a phosphate buffer, and
a mass concentration of the sponge spicules in the phosphate buffer is 10-100 mg/mL.
US Pat. No. 10,557,178

PROBES FOR IDENTIFYING GEOGRAPHICAL DISTRIBUTION AND MOLECULAR EPIDEMIOLOGY OF VIRAL HEMORRHAGIC SEPTICEMIA VIRUS (VHSV) AND USES THEREOF

NATIONAL INSTITUTE OF FIS...

1. A method of detecting single-nucleotide polymorphisms (SNPs), which determine a region-specific genotype of viral hemorrhagic septicemia virus (VHSV), to identify a geographic region of origin of a VHSV isolate distinguished from other geographic regions of origin of VHSV, using a single probe which is effective for identifying VHSV in all such geographic regions, the method comprising the steps of:(a) synthesizing target DNA by reverse transcribing RNA extracted from the VHSV isolate;
(b) hybridizing the target DNA to a PNA probe which has a nucleobase sequence consisting of the nucleobase sequence set forth in SEQ ID NO: 1 and a reporter and/or a quencher attached to the PNA probe, which is capable of hybridizing under strict conditions to a sequence fragment having C755A and A756G single-nucleotide polymorphism mutations in the G-protein sequence of the VHSV isolate;
(c) obtaining a temperature-dependent melting curve while increasing the temperature of a hybridized product resulting from step (b); and
(d) analyzing the obtained melting curve to identify the geographic region of origin of the VHSV isolate, wherein the melting peak of the melting curve correlates to the origin of the VHSV isolate and distinguishes that the isolate originated from either (i) Korea, (ii) USA, Canada, Japan, or China, or (iii) Europe.
US Pat. No. 10,556,411

WATER BARRIER LAMINATE

TOYO SEIKAN GROUP HOLDING...

1. A water barrier laminate comprising a plastic base material, the water barrier laminate being adapted for use in an arrangement wherein an outer surface of the water barrier laminate faces an atmosphere having a relatively high water content and an inner surface of the water barrier laminate faces an atmosphere having a relatively low water content, wherein:a first inorganic barrier layer, a water-trapping layer and a second inorganic barrier layer are formed in this order on the inner surface side of said plastic base material;
an auxiliary water-trapping layer is formed on said inner surface side of said second inorganic barrier layer to trap water from the side surface; and
said auxiliary water-trapping layer faces the atmosphere having the relatively low water content or is located in a region at a distance of not more than 20 ?m from the surface that faces the atmosphere having the relatively low water content.
US Pat. No. 10,555,898

TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES

DFB SORIA, LLC, Fort Wor...

1. A method of treating a skin malignancy in a subject in need of treatment, the method comprising topically administering to an affected area of the subject a hydrophobic composition comprising a plurality of nanoparticles of non-solubilized taxane, a hydrophobic carrier, and 5% w/w to 24% w/w of one or more volatile silicone fluids, wherein the plurality of nanoparticles penetrate into the dermal or epidermal portions of the affected area of the subject, wherein the nanoparticles of non-solubilized taxane are uncoated (neat) individual particles of non-solubilized taxane, and wherein the non-solubilized taxane is not bound to or conjugated to any substance.
US Pat. No. 10,556,924

PROCESS FOR THE PREPARATION OF PASIREOTIDE

BIOPHORE INDIA PHARMACEUT...

1. A process for preparing Pasireotide of formula (11) comprising the steps of:(a) treating 2-chloro Trityl Resin (CTC resin) with Fmoc-Tyr(Bzl)-OH in presence of DCM and N,N-diisopropylethylamine (DIPEA) to obtain Fmoc-Tyr(Bzl)-CTC resin;
(b) coupling Fmoc-Lys(Boc)-OH with Fmoc-Tyr(Bzl)-CTC resin in presence of HOBt and HBTU, DMF, and N,N-diisopropyl ethyl amine (DIPEA) to obtain Fmoc-Lys(Boc)-Tyr(Bzl)-CTC resin;
(c) coupling of Fmoc-D-Trp(Boc)-OH with Fmoc-Lys(Boc)-Tyr(Bzl)-CTC resin in presence of HOBt and TBTU in DMF and N,N-diisopropyl ethylamine to obtain Fmoc-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-CTC resin;
(d) coupling Fmoc-Phg-OH with Fmoc-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-CTC resin in presence of HOAT and DIC in DMF and N-Methyl morpholine (NMM) to obtain Fmoc-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-CTC resin;
(e) coupling Fmoc-Pro(4-OP)-OH with Fmoc-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-CTC-resin in presence of HOBt and DIC in DMF and N-Methyl morpholine (NMM) to obtain Fmoc-Pro (4-OP)-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-CTC resin, wherein P is a hydrogen or a hydroxyl protecting group;
(f) coupling Fmoc-Phe-OH with Pro(4-OP)-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-CTC resin in presence of HBTU and HOBt in DMF and N,N-diisopropyl ethylamine (DIPEA) to obtain Fmoc-Phe-Pro(4-OP)-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-CTC resin wherein P is a hydrogen or a hydroxyl protecting group;
(g) cleaving the resin from Fmoc-Phe-Pro(4-OP)-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-CTC resin using TFA in DCM followed by neutralizing using DIPEA in DCM to obtain a solid H-Phe-Pro(4-OP)Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-OH wherein P is a hydrogen or a hydroxyl protecting group;
(h) cyclizing of H-Phe-Pro-(4-OP)-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)-OH in presence of HATU and HOAT in DMF and N,N-diisopropyl ethyl amine (DIPEA) to obtain cyclo(Phe-Pro(4-OP)-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)) (compound 8) wherein P is a hydrogen or a hydroxyl protecting group;
(i) coupling of cyclo(Phe-Pro(4-OP)-Phg-D-Trp(Boc)-Lys(Boc)-Tyr(Bzl)) (compound 8) with N-Boc diaminoethane in presence of triphosgene in THF to give a chlorocarbonate intermediate wherein P is a hydrogen or a hydroxyl protecting group;
(j) deprotecting the amine protecting groups in the chlorocarbonate intermediate by treating with TFA/TIS and water to give crude Pasireotide;
(k) optionally, purifying crude Pasireotide by preparative HPLC and further converting into Pasireotide salt by treating with desired acid.
US Pat. No. 10,557,180

HEAT TREATING DEVICE

IHI CORPORATION, Tokyo (...

1. A heat treating device, comprising:a heating furnace which heats a workpiece;
an ammonia gas supply device which supplies an ammonia gas to the heating furnace which nitrides the workpiece in the heating furnace; and
a thermal decomposition furnace which thermally decomposes the ammonia gas discharged from the heating furnace after the nitriding,wherein the thermal decomposition furnace includes:a reactant which promotes a thermal decomposition reaction of the ammonia gas,
a heating chamber which accommodates and heats the reactant,
an introduction pipe through which the ammonia gas is introduced to the heating chamber,
a vacuum container which surrounds the heating chamber, and
a vacuum pump which evacuates the inside of the vacuum container.
US Pat. No. 10,555,900

FORMULATIONS AND METHODS FOR VAGINAL DELIVERY OF ANTIPROGENSTINS

ALLERGAN PHARMACEUTICALS ...

1. A pharmaceutical formulation for vaginal use, comprising a mucoadhesive capsule comprising pullulan and a capsule fill formulation comprising CDB-2914 or a pharmaceutically acceptable salt thereof dispersed in an excipient mixture comprising (a) isopropyl myristate or isopropyl palmitate and (b) a polyethylene glycol, wherein the capsule fill formulation produces an increased AUC with vaginal administration as compared to a capsule fill formulations lacking isopropyl myristate or isopropyl palmitate.
US Pat. No. 10,556,926

SYNTHETIC ARTIFICIAL PEPTIDES WITH ANTIMICROBIAL EFFECT

Fraunhofer-Gesellschaft, ...

1. A peptide consisting of an amino-terminal region A, a carboxy-terminal region C and, in between, a region B, the peptide having the general formulaAxByCz,
with 3?x?7, 3?z?7 and 5?y?10,
wherein the amino acids of A and C, independently of one another, are exclusively selected from the group consisting of Lys, Arg and combinations thereof and wherein the amino acids of B are exclusively selected from the group consisting of Val, Ile and combinations of at least two of Val, Leu, and Ile, and wherein the peptide on the C-terminus is formed as carboxamide.
US Pat. No. 10,555,901

LIQUISOFT CAPSULES

PATHEON SOFTGELS INC, Hi...

1. An oral pharmaceutical composition suitable for chewing, sucking, or buccal dissolution comprising a soft shell encapsulating a liquid matrix,the shell comprising:
(a) about 20% gelatin, 150 Bloom;
(b) about 9% gelatin, 100 Bloom;
(c) about 5% hydrolyzed collagen;
(d) about 17% lycasin;
(e) about 25% glycerin;
(f) about 0.5% citric acid;
(g) about 2.5% about xylitol,
(h) about 0.2% sucralose; and
(i) about 21% water; and
the matrix comprising:
(j) about 21% polyethylene glycol 500,
(k) about 8% propylene glycol;
(l) about 1% polyvinylpyrrolidone K30;
(m) about 58% lycasin;
(n) about 1% citric acid;
(o) about 1% lactic acid;
(p) about 0.6% sucralose,
(q) about 0.6% acesulfame potassium;
(r) about 5% water;
(s) about 1% dextromethorphan hydrobromide; and
(t) about 0.1% menthol.
US Pat. No. 10,556,927

CONOTOXIN PEPTIDE ?-CPTX-BTL03, PREPARATION METHOD THEREFOR, AND USES THEREOF

BGI SHENZHEN, (CN)

1. A conotoxin peptide ?-CPTx-btl03, the conotoxin peptide ?-CPTx-btl03 being derived from a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 by substitution of one or more amino acids in the amino acid sequence of SEQ ID NO: 1 of the polypeptide and having the function of the polypeptide,wherein the substitution of one or more amino acids is selected from the group consisting of: (i) substitution of the arginine at position 1 with lysine; (ii) substitution of the asparagine at position 3 with glutamine; (iii) substitution of the threonine at position 7 with serine; (iv) substitution of the leucine at position 9 or 29 with isoleucine or valine; (v) substitution of the glutamine at position 13 or 19 with asparagine; (vi) substitution of the valine at position 15 or 22 with leucine or isoleucine; (vii) substitution of the isoleucine at position 20 with leucine or valine; and (viii) substitution of the lysine at position 27 with arginine, and
wherein the amino acid sequence of the polypeptide contains three pairs of disulfide bonds.
US Pat. No. 10,555,902

STABLE FINGOLIMOD DOSAGE FORMS

Handa Pharmaceuticals LLC...

1. A method for treating multiple sclerosis comprising the step of administering to a patient in need of such treatment a solid oral dosage form comprising 0.1 mg to 1 mg of fingolimod lauryl sulfate salt and at least one pharmaceutically acceptable excipient, wherein following a single dose administration of the solid oral dosage form to healthy human adults under fasting conditions, the time to maximum fingolimod concentration (Tmax) is about 10 to about 35 hours, the dose adjusted maximum fingolimod concentration (Cmax/dose) is about 0.55 to about 1.5 ng/ml/mg, and the dose adjusted area under the plasma concentration-time curve (AUC0-?/dose) is about 125 to about 275 ng·hr/ml/mg.
US Pat. No. 10,556,928

STABILIZED PEPTOID-PEPTIDE HYBRIDS AND USES THEREOF

H. LEE MOFFITT CANCER CEN...

1. A method of positional library scanning for identification of a peptoid or a peptoid-peptide hybrid having a desired biological activity, the method comprising:a. producing a library of the peptoids having a core peptoid structure or the peptoid-peptide hybrids having a core peptoid-peptide structure, wherein the library consists of compounds having various combinations of possible side chains on a number of possible substitution positions on the core peptoid or the core peptoid-peptide hybrid,
wherein each peptoid comprises a plurality of N-substituted glycines, wherein at least two of the N-substituted glycines are linked to each other by an intramolecular cross-link between the N-substitutions, and wherein the length and geometry of the cross-link pre-organizes the peptoid into a desired conformation, and
wherein each peptoid-peptide hybrid comprises a plurality of amino acids and a plurality of N-substituted glycines, wherein at least two residues from the plurality of amino acids and the plurality of N-substituted glycines are linked to each other by an intramolecular cross-link, and wherein the length and geometry of the intramolecular cross-link provides stability to the peptoid-peptide hybrid,
b. producing a positional scanning library comprising an array of spots containing the peptoids or the peptoid-peptide hybrids,
c. conducting an assay for the desired biological activity to identify one or more spots on the positional scanning library that display the desired biological activity, and
d. further testing the compounds present in the spots that display the desired biological activity to identify the compounds having the desired biological activity.